34.2 32.7 0000920148 12/31 2024 Q1 false 0000920148 2024-01-01 2024-03-31 0000920148 2024-04-29 xbrli:shares 0000920148 2024-03-31 iso4217:USD 0000920148 2023-12-31 0000920148 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0000920148 us-gaap:CommonStockMember 2022-12-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000920148 us-gaap:RetainedEarningsMember 2022-12-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000920148 2022-12-31 0000920148 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000920148 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000920148 us-gaap:CommonStockMember 2023-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000920148 us-gaap:RetainedEarningsMember 2023-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000920148 2023-03-31 0000920148 us-gaap:CommonStockMember 2023-12-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000920148 us-gaap:RetainedEarningsMember 2023-12-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000920148 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000920148 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000920148 us-gaap:CommonStockMember 2024-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000920148 us-gaap:RetainedEarningsMember 2024-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-03-31 0000920148 us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-03-31 0000920148 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2024-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2023-03-31 0000920148 lh:DiagnosticsMember 2024-01-01 2024-03-31 xbrli:pure 0000920148 lh:DrugDevelopmentMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember 2023-01-01 2023-03-31 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:CovanceDrugDevelopmentMember 2023-01-01 2023-03-31 0000920148 2023-06-30 0000920148 lh:FortreaRevolverDue2028Member 2023-06-30 0000920148 lh:FortreaTermLoanAMaturing2028Member 2023-06-30 0000920148 lh:FortreaTermLoanBMaturing2028Member 2023-06-30 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember lh:ClientMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember srt:EuropeMember lh:ClientMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:OthercountriesMember lh:ClientMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ClientMember 2024-01-01 2024-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember lh:ClientMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember srt:EuropeMember lh:ClientMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:OthercountriesMember lh:ClientMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ClientMember 2023-01-01 2023-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember srt:EuropeMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember lh:OthercountriesMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember 2024-01-01 2024-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember srt:EuropeMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember lh:OthercountriesMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember us-gaap:SelfPayMember 2023-01-01 2023-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember lh:MedicareandMedicaidMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember srt:EuropeMember lh:MedicareandMedicaidMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:OthercountriesMember lh:MedicareandMedicaidMember 2024-01-01 2024-03-31 0000920148 lh:MedicareandMedicaidMember 2024-01-01 2024-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember lh:MedicareandMedicaidMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember srt:EuropeMember lh:MedicareandMedicaidMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:OthercountriesMember lh:MedicareandMedicaidMember 2023-01-01 2023-03-31 0000920148 lh:MedicareandMedicaidMember 2023-01-01 2023-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember lh:ThirdpartyMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ThirdpartyMember srt:EuropeMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ThirdpartyMember lh:OthercountriesMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ThirdpartyMember 2024-01-01 2024-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember lh:ThirdpartyMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ThirdpartyMember srt:EuropeMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ThirdpartyMember lh:OthercountriesMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:ThirdpartyMember 2023-01-01 2023-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember srt:EuropeMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:OthercountriesMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember 2024-01-01 2024-03-31 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember srt:EuropeMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:OthercountriesMember 2023-01-01 2023-03-31 0000920148 srt:NorthAmericaMember lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:DrugDevelopmentMember 2024-01-01 2024-03-31 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:DrugDevelopmentMember srt:EuropeMember 2024-01-01 2024-03-31 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:DrugDevelopmentMember lh:OthercountriesMember 2024-01-01 2024-03-31 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:DrugDevelopmentMember 2024-01-01 2024-03-31 0000920148 srt:NorthAmericaMember lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:CovanceDrugDevelopmentMember 2023-01-01 2023-03-31 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:CovanceDrugDevelopmentMember srt:EuropeMember 2023-01-01 2023-03-31 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:CovanceDrugDevelopmentMember lh:OthercountriesMember 2023-01-01 2023-03-31 0000920148 srt:NorthAmericaMember 2024-01-01 2024-03-31 0000920148 srt:EuropeMember 2024-01-01 2024-03-31 0000920148 lh:OthercountriesMember 2024-01-01 2024-03-31 0000920148 srt:NorthAmericaMember 2023-01-01 2023-03-31 0000920148 srt:EuropeMember 2023-01-01 2023-03-31 0000920148 lh:OthercountriesMember 2023-01-01 2023-03-31 0000920148 country:US 2024-01-01 2024-03-31 0000920148 country:US 2023-01-01 2023-03-31 0000920148 lh:DiagnosticsMember 2024-03-31 0000920148 lh:DiagnosticsMember 2023-12-31 0000920148 lh:DrugDevelopmentMember 2024-03-31 0000920148 lh:DrugDevelopmentMember 2023-12-31 0000920148 us-gaap:AccountsReceivableMember 2024-01-01 2024-03-31 0000920148 lh:UnbilledContractsReceivableMember 2024-01-01 2024-03-31 0000920148 us-gaap:NotesReceivableMember 2024-01-01 2024-03-31 0000920148 lh:BaystateMedicalCenterMember 2024-03-31 0000920148 lh:ProvidenceMedicalFoundationMember 2024-03-31 0000920148 lh:WestpacLabsInc.Member 2024-03-31 0000920148 lh:OtheracquireesMember 2024-01-01 2024-03-31 0000920148 srt:MinimumMember us-gaap:CustomerListsMember 2024-01-01 2024-03-31 0000920148 srt:MaximumMember us-gaap:CustomerListsMember 2024-01-01 2024-03-31 0000920148 lh:BaystateMedicalCenterMember 2024-01-01 2024-03-31 0000920148 lh:WestpacLabsInc.Member 2024-01-01 2024-03-31 0000920148 lh:ProvidenceMedicalFoundationMember 2024-01-01 2024-03-31 0000920148 us-gaap:GoodwillMember 2024-01-01 2024-03-31 0000920148 us-gaap:OtherNoncurrentAssetsMember 2024-01-01 2024-03-31 0000920148 lh:OperatingLeaseLiabilityMember 2024-01-01 2024-03-31 0000920148 us-gaap:OtherNoncurrentLiabilitiesMember 2024-01-01 2024-03-31 0000920148 lh:OtherAcquisitionsMember 2024-03-31 0000920148 us-gaap:GoodwillMember 2023-01-01 2023-03-31 0000920148 us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-03-31 0000920148 us-gaap:AccruedLiabilitiesMember 2023-01-01 2023-03-31 0000920148 us-gaap:OtherNoncurrentLiabilitiesMember 2023-01-01 2023-03-31 0000920148 lh:LabCorpDiagnosticsMember 2023-12-31 0000920148 lh:CovanceDrugDevelopmentMember 2023-12-31 0000920148 lh:CovanceDrugDevelopmentMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember 2024-03-31 0000920148 lh:CovanceDrugDevelopmentMember 2024-03-31 0000920148 us-gaap:CustomerRelationshipsMember 2024-03-31 0000920148 us-gaap:CustomerRelationshipsMember 2023-12-31 0000920148 lh:PatentsLicensesAndTechnologyMember 2024-03-31 0000920148 lh:PatentsLicensesAndTechnologyMember 2023-12-31 0000920148 us-gaap:NoncompeteAgreementsMember 2024-03-31 0000920148 us-gaap:NoncompeteAgreementsMember 2023-12-31 0000920148 us-gaap:TradeNamesMember 2024-03-31 0000920148 us-gaap:TradeNamesMember 2023-12-31 0000920148 us-gaap:UseRightsMember 2024-03-31 0000920148 us-gaap:UseRightsMember 2023-12-31 0000920148 us-gaap:LicensingAgreementsMember 2024-03-31 0000920148 us-gaap:LicensingAgreementsMember 2023-12-31 0000920148 lh:InProcessRAAndMediaMember 2024-03-31 0000920148 lh:InProcessRAAndMediaMember 2023-12-31 0000920148 us-gaap:OtherCurrentLiabilitiesMember 2024-03-31 0000920148 us-gaap:OtherCurrentLiabilitiesMember 2023-12-31 0000920148 us-gaap:InterestRateSwapMember 2024-03-31 0000920148 us-gaap:InterestRateSwapMember 2023-12-31 0000920148 us-gaap:RevolvingCreditFacilityMember 2024-03-31 utr:Rate 0000920148 us-gaap:CommonStockMember 2023-12-31 0000920148 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000920148 us-gaap:CommonStockMember 2024-03-31 0000920148 us-gaap:SubsequentEventMember 2024-04-11 2024-04-11 0000920148 us-gaap:SubsequentEventMember 2024-04-11 0000920148 lh:InitialDamagesMember 2024-01-01 2024-03-31 0000920148 lh:EnhancedDamagesMember 2024-01-01 2024-03-31 0000920148 us-gaap:FairValueInputsLevel1Member 2024-03-31 0000920148 us-gaap:FairValueInputsLevel2Member 2024-03-31 0000920148 us-gaap:FairValueInputsLevel3Member 2024-03-31 0000920148 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000920148 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000920148 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000920148 lh:Seniornotesdue2027Member 2024-03-31 0000920148 lh:SeniorNotesDue2022Member lh:A2018SwapAgreementsMember 2024-03-31 0000920148 lh:SeniorNotesDue2024Member lh:A2022SwapAgreementsMember 2024-03-31 0000920148 lh:DiagnosticsMember us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000920148 lh:DiagnosticsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000920148 lh:DrugDevelopmentMember us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000920148 lh:DrugDevelopmentMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000920148 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-03-31 0000920148 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-03-31 0000920148 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000920148 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000920148 us-gaap:CorporateMember 2024-01-01 2024-03-31 0000920148 us-gaap:CorporateMember 2023-01-01 2023-03-31 0000920148 us-gaap:SubsequentEventMember 2024-04-01 2024-04-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File Number 1-11353
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact name of registrant as specified in its charter)

Delaware |  | 13-3757370
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

358 South Main Street |  |
Burlington, | North Carolina |  | 27215
(Address of principal executive offices) |  | (Zip Code)

(Registrant's telephone number, including area code) 336-229-1127
Securities registered pursuant to Section 12(b) of the Exchange Act.
Title of Each Class Trading Symbol Name of exchange on which registered
Common Stock, $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐
Non-accelerated filer | ☐ | Smaller reporting company | ☐
|  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

Class |  | Shares Outstanding |  | Date
Common Stock $0.10 par value |  | 84,293,628 |  | April 29, 2024

INDEX
INDEX
PART I. FINANCIAL INFORMATION

Item 1. | Financial Statements (unaudited) |
| Condensed Consolidated Balance Sheets | 2
| March 31, 2024 and December 31, 2023 |
| Condensed Consolidated Statements of Operations | 3
| Three Months Ended March 31, 2024 and 2023 |
| Condensed Consolidated Statements of Comprehensive Earnings | 4
| Three Months Ended March 31, 2024 and 2023 |
| Condensed Consolidated Statements of Changes in Shareholders’ Equity | 5
| Three Months Ended March 31, 2024 and 2023 |
| Condensed Consolidated Statements of Cash Flows | 6
| Three Months Ended March 31, 2024 and 2023 |
| Notes to Unaudited Condensed Consolidated Financial Statements | 7
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21
Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 28
Item 4. | Controls and Procedures | 29

PART II. OTHER INFORMATION

Item 1. | Legal Proceedings | 30
Item 1A. | Risk Factors | 30
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 31
Item 5. | Other Information | 31
Item 6. | Exhibits | 31

1

INDEX
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions)
(unaudited)

| March 31, 2024 |  | December 31, 2023
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 99.3 |  |  | $ | 536.8 |
Accounts receivable, net | 2,083.7 |  |  | 1,913.3 |
Unbilled services | 120.4 |  |  | 185.4 |
Supplies inventory | 475.0 |  |  | 474.6 |
Prepaid expenses and other | 678.1 |  |  | 655.3 |
Total current assets | 3,456.5 |  |  | 3,765.4 |
Property, plant and equipment, net | 2,897.8 |  |  | 2,911.8 |
Goodwill, net | 6,218.9 |  |  | 6,142.5 |
Intangible assets, net | 3,394.1 |  |  | 3,342.0 |
Joint venture partnerships and equity method investments | 17.7 |  |  | 26.9 |
Other assets, net | 546.0 |  |  | 536.5 |
Total assets | $ | 16,531.0 |  |  | $ | 16,725.1 |
LIABILITIES AND SHAREHOLDERS’ EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 695.5 |  |  | $ | 827.5 |
Accrued expenses and other | 649.3 |  |  | 804.0 |
Unearned revenue | 377.5 |  |  | 421.7 |
Short-term operating lease liabilities | 171.3 |  |  | 165.8 |
Short-term finance lease liabilities | 6.4 |  |  | 6.4 |
Short-term borrowings and current portion of long-term debt | 2,041.5 |  |  | 999.8 |
Total current liabilities | 3,941.5 |  |  | 3,225.2 |
Long-term debt, less current portion | 3,047.6 |  |  | 4,054.7 |
Operating lease liabilities | 624.6 |  |  | 648.9 |
Financing lease liabilities | 77.1 |  |  | 78.6 |
Deferred income taxes and other tax liabilities | 397.2 |  |  | 417.9 |
Other liabilities | 468.2 |  |  | 409.3 |
Total liabilities | 8,556.2 |  |  | 8,834.6 |
Commitments and contingent liabilities |  |  |
Noncontrolling interest | 15.2 |  |  | 15.5 |
Shareholders’ equity: |  |  |
Common stock, $0.10 par value, 84.3 and 83.9 shares outstanding at March 31, 2024, and December 31, 2023, respectively | 7.7 |  |  | 7.7 |
Additional paid-in capital | 82.0 |  |  | 38.4 |
Retained earnings | 8,055.3 |  |  | 7,888.2 |
Accumulated other comprehensive loss | (185.4) |  |  | (59.3) |
Total shareholders’ equity | 7,959.6 |  |  | 7,875.0 |
Total liabilities and shareholders’ equity | $ | 16,531.0 |  |  | $ | 16,725.1 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data)
(unaudited)

|  |  | Three Months Ended March 31,
|  |  |  |  | 2024 |  | 2023
Revenues |  |  |  |  | $ | 3,176.6 |  |  | $ | 3,037.8 |
Cost of revenues |  |  |  |  | 2,279.3 |  |  | 2,187.7 |
Gross profit |  |  |  |  | 897.3 |  |  | 850.1 |
Selling, general and administrative expenses |  |  |  |  | 508.4 |  |  | 457.2 |
Amortization of intangibles and other assets |  |  |  |  | 60.1 |  |  | 53.4 |
Goodwill and other asset impairments |  |  |  |  | 2.5 |  |  | 2.2 |
Restructuring and other charges |  |  |  |  | 5.0 |  |  | 7.5 |
Operating income |  |  |  |  | 321.3 |  |  | 329.8 |
Other income (expense): |  |  |  |  |  |  |
Interest expense |  |  |  |  | (46.9) |  |  | (50.7) |
Investment income |  |  |  |  | 2.9 |  |  | 2.2 |
Equity method income (expense), net |  |  |  |  | 0.1 |  |  | (2.1) |
Other, net |  |  |  |  | 20.0 |  |  | (6.9) |
Earnings from continuing operations before income taxes |  |  |  |  | 297.4 |  |  | 272.3 |
Provision for income taxes |  |  |  |  | 69.1 |  |  | 63.9 |
Earnings from continuing operations |  |  |  |  | 228.3 |  |  | 208.4 |
Earnings from discontinued operations, net of tax |  |  |  |  | — |  |  | 4.9 |
Net earnings |  |  |  |  | 228.3 |  |  | 213.3 |
Less: Net earnings attributable to the noncontrolling interest |  |  |  |  | (0.3) |  |  | (0.4) |
Net earnings attributable to Laboratory Corporation of America Holdings |  |  |  |  | $ | 228.0 |  |  | $ | 212.9 |
Basic earnings per share: |  |  |  |  |  |  |
Basic earnings per share continuing operations |  |  |  |  | $ | 2.71 |  |  | $ | 2.35 |
Basic earnings per share discontinued operations |  |  |  |  | $ | — |  |  | $ | 0.06 |
Basic earnings per share |  |  |  |  | $ | 2.71 |  |  | $ | 2.41 |
Diluted earnings per share: |  |  |  |  |  |  |
Diluted earnings per share continuing operations |  |  |  |  | $ | 2.69 |  |  | $ | 2.34 |
Diluted earnings per share discontinued operations |  |  |  |  | $ | — |  |  | $ | 0.05 |
Diluted earnings per share |  |  |  |  | $ | 2.69 |  |  | $ | 2.39 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS
(in millions)
(unaudited)

|  |  | Three Months Ended March 31,
|  |  |  |  | 2024 |  | 2023
Net earnings |  |  |  |  | $ | 228.3 |  |  | $ | 213.3 |
Foreign currency translation adjustments |  |  |  |  | (124.3) |  |  | 48.1 |
Net benefit plan adjustments |  |  |  |  | (2.4) |  |  | 1.2 |
Other comprehensive earnings (loss) before tax |  |  |  |  | (126.7) |  |  | 49.3 |
Provision for income tax related to items of comprehensive earnings |  |  |  |  | 0.6 |  |  | (0.3) |
Other comprehensive earnings (loss), net of tax |  |  |  |  | (126.1) |  |  | 49.0 |
Comprehensive earnings |  |  |  |  | 102.2 |  |  | 262.3 |
Less: Net earnings attributable to the noncontrolling interest |  |  |  |  | (0.3) |  |  | (0.4) |
Comprehensive earnings attributable to Laboratory Corporation of America Holdings |  |  |  |  | $ | 101.9 |  |  | $ | 261.9 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
SHAREHOLDERS’ EQUITY
(in millions)
(unaudited)

| Common Stock |  | Additional Paid-in Capital |  | Retained Earnings |  | Accumulated Other Comprehensive Earnings (Loss) |  | Total Shareholders’ Equity |  |
BALANCE AT DECEMBER 31, 2022 | $ | 8.1 |  |  | $ | — |  |  | $ | 10,581.7 |  |  | $ | (493.2) |  |  | $ | 10,096.6 |  |  |
Net earnings attributable to Laboratory Corporation of America Holdings | — |  |  | — |  |  | 212.9 |  |  | — |  |  | 212.9 |  |  |
Other comprehensive earnings (loss), net of tax | — |  |  | — |  |  | — |  |  | 49.0 |  |  | 49.0 |  |  |
Dividends declared | — |  |  | — |  |  | (64.7) |  |  | — |  |  | (64.7) |  |  |
Issuance of common stock under employee stock plans | — |  |  | 27.6 |  |  | — |  |  | — |  |  | 27.6 |  |  |
Net share settlement tax payments from issuance of stock to employees | — |  |  | (20.5) |  |  | — |  |  | — |  |  | (20.5) |  |  |
Stock compensation | — |  |  | 40.6 |  |  | — |  |  | — |  |  | 40.6 |  |  |
BALANCE AT MARCH 31, 2023 | $ | 8.1 |  |  | $ | 47.7 |  |  | $ | 10,729.9 |  |  | $ | (444.2) |  |  | $ | 10,341.5 |  |  |
BALANCE AT DECEMBER 31, 2023 | $ | 7.7 |  |  | $ | 38.4 |  |  | $ | 7,888.2 |  |  | $ | (59.3) |  |  | $ | 7,875.0 |  |  |
Net earnings attributable to Laboratory Corporation of America Holdings | — |  |  | — |  |  | 228.0 |  |  | — |  |  | 228.0 |  |  |
Other comprehensive earnings (loss), net of tax | — |  |  | — |  |  | — |  |  | (126.1) |  |  | (126.1) |  |  |
Dividends declared | — |  |  | — |  |  | (60.9) |  |  | — |  |  | (60.9) |  |  |
Issuance of common stock under employee stock plans | — |  |  | 26.7 |  |  | — |  |  | — |  |  | 26.7 |  |  |
Net share settlement tax payments from issuance of stock to employees | — |  |  | (14.7) |  |  | — |  |  | — |  |  | (14.7) |  |  |
Stock compensation | — |  |  | 31.6 |  |  | — |  |  | — |  |  | 31.6 |  |  |
BALANCE AT MARCH 31, 2024 | $ | 7.7 |  |  | $ | 82.0 |  |  | $ | 8,055.3 |  |  | $ | (185.4) |  |  | $ | 7,959.6 |  |  |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)

| Three Months Ended March 31,
| 2024 |  | 2023
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
Net earnings | $ | 228.3 |  |  | $ | 213.3 |
Earnings from discontinued operations, net of tax | — |  |  | (4.9) |
Adjustments to reconcile net earnings to net cash provided by operating activities: |  |  |
Depreciation and amortization | 154.5 |  |  | 142.1 |
Stock compensation | 31.6 |  |  | 32.9 |
Operating lease right-of-use asset expense | 44.1 |  |  | 40.5 |
Goodwill and other asset impairments | 2.5 |  |  | 2.2 |
Deferred income taxes | (19.5) |  |  | 27.2 |
Other | (3.0) |  |  | 9.6 |
Change in assets and liabilities (net of effects of acquisitions and divestitures): |  |  |
Increase in accounts receivable | (187.1) |  |  | (108.4) |
Decrease in unbilled services | 63.9 |  |  | 56.9 |
Increase in supplies inventory | (0.6) |  |  | (10.0) |
Increase in prepaid expenses and other | (24.9) |  |  | (57.5) |
Decrease in accounts payable | (121.1) |  |  | (77.7) |
(Decrease) increase in unearned revenue | (41.6) |  |  | 16.3 |
Decrease in accrued expenses and other | (156.9) |  |  | (96.8) |
Net cash provided by (used for) continuing operating activities | (29.8) |  |  | 185.7 |
Net cash used for discontinued operating activities | — |  |  | (64.5) |
Net cash provided by (used for) operating activities | (29.8) |  |  | 121.2 |
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
Capital expenditures | (133.8) |  |  | (78.2) |
Proceeds from sale of assets | 0.1 |  |  | 0.1 |
Proceeds from sale of business | 13.5 |  |  | — |
Investments in equity affiliates | (13.7) |  |  | (6.1) |
Acquisition of businesses, net of cash acquired | (259.2) |  |  | 0.2 |
Net cash used for continuing investing activities | (393.1) |  |  | (84.0) |
Net cash used for discontinued investing activities | — |  |  | (15.7) |
Net cash used for investing activities | (393.1) |  |  | (99.7) |
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
Proceeds from revolving credit facilities | 253.2 |  |  | 827.9 |
Payments on revolving credit facilities | (210.8) |  |  | (827.9) |
Net share settlement tax payments from issuance of stock to employees | (14.7) |  |  | (20.5) |
Net proceeds from issuance of stock to employees | 26.7 |  |  | 27.6 |
Dividends paid | (62.1) |  |  | (64.4) |
Other | (4.0) |  |  | (3.3) |
Net cash used for continuing financing activities | (11.7) |  |  | (60.6) |
Net cash provided by discontinued financing activities | — |  |  | — |
Net cash used for financing activities | (11.7) |  |  | (60.6) |
Effect of exchange rate changes on cash and cash equivalents | (2.9) |  |  | 3.0 |
Net decrease in cash and cash equivalents | (437.5) |  |  | (36.1) |
Cash and cash equivalents at beginning of period | 536.8 |  |  | 430.0 |
Less: Cash and cash equivalents of discontinued operations at end of period | $ | — |  |  | $ | 99.1 |
Cash and cash equivalents at end of period | $ | 99.3 |  |  | $ | 294.8 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
1. BASIS OF FINANCIAL STATEMENT PRESENTATION
Laboratory Corporation of America® Holdings (Labcorp® or the Company) is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceuitcal companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives.
The Company reports its business in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), formerly Drug Development. For further financial information about these segments, see Note 12 (Business Segment Information) to the Condensed Consolidated Financial Statements. During the three months ended March 31, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. During the three months ended March 31, 2023, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company.
The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles.
The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and do not contain certain information included in the Company’s fiscal year 2023 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report.
The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value, or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements.
The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the period. Resulting translation adjustments are included in “Accumulated other comprehensive income (loss).”
2. DISCONTINUED OPERATIONS
On June 30, 2023 (the Distribution Date), Labcorp completed the previously announced separation (the Separation) from the Company of Fortrea Holdings Inc. (Fortrea), formerly the Company's Clinical Development and Commercialization Services (CDCS) business, into a separate, publicly-traded company. All historical operating results of Fortrea are presented as Discontinued Operations, net of tax, in the consolidated statement of operations. The spin-off is expected to be treated as tax-free for the Company and its shareholders for U.S. federal income tax purposes.
A discontinued operation may include a component or a group of components of the Company's operations. A disposal of a component or a group of components is reported in discontinued operations if the disposal represents a strategic shift that has or will have a major effect on the Company's operations and financial results when the following occurs: (1) a component (or group of components) meets the criteria to be classified as held for sale; (2) the component or group of components is disposed of by sale; or (3) the component or group of components is disposed of other than by sale (for example, by abandonment or in a distribution to owners in a spin-off). For any component classified as held for sale or disposed of by sale or other than by sale, qualifying for presentation as a discontinued operation, the Company reports the results of operations of the discontinued operations (including any gain or loss recognized on the disposal or loss recognized on classification as held for sale of a discontinued operation), less applicable income taxes (benefit), as a separate component in the consolidated statement of operations for current and all prior periods presented. The Company also reports assets and liabilities associated with discontinued operations as separate line items on the consolidated balance sheet for prior periods.
7

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
The spin-off of Fortrea from Labcorp was achieved through the Company’s pro-rata distribution of 100% of the outstanding shares of Fortrea common stock to holders of record of Labcorp common stock. Each holder of record of Labcorp common stock received one share of Fortrea common stock for every share of Labcorp common stock held at 5:00 p.m., Burlington, North Carolina, time on June 20, 2023, the record date for the distribution.
In June 2023, Fortrea, prior to the Separation and while a subsidiary of the Company, issued $570.0 of 7.500% senior secured notes due 2030 (the Fortrea Notes). The proceeds from the Fortrea Notes were used to fund cash payments of approximately $1,600.0 to the Company in connection with the Separation. The Company does not guarantee the Fortrea Notes following the Separation. Also in June 2023, Fortrea entered into three floating secured overnight financing rate (SOFR) credit facilities totaling $1,520.0. These are comprised of a $450.0 Revolver maturing June 30, 2028; a $500.0 Term Loan A maturing June 30, 2028; and a $570.0 Term Loan B maturing June 30, 2030.
In connection with the spin-off, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Company’s relationship with Fortrea after the spin-off, including a separation and distribution agreement, a tax matters agreement, an employee matters agreement, and a transition services agreement. These agreements contain the key provisions relating to the spin-off, including provisions relating to the principal intercompany transactions required to effect the spin-off, the conditions to the spin-off and provisions governing the relationship between Fortrea and the Company after the spin-off. The costs to provide these services are included in operating income but the service fees are included in other income.
Financial Information of Discontinued Operations
Earnings from Discontinued Operations, Net of Tax in the Consolidated Statements of Operations reflect the after-tax results of Fortrea's business and Separation-related fees, and do not include any allocation of general corporate overhead expense or interest expense of the Company.
The following table summarizes the significant line items included in Earnings from Discontinued Operations, Net of Tax in the Consolidated Statements of Operations for the three months ended March 31, 2023:

| Three Months Ended March 31, 2023 |
Revenues | $ | 740.1 |  |  |  |  |  |  |
Cost of revenues | 615.5 |  |  |  |  |  |  |
Gross profit | 124.6 |  |  |  |  |  |  |
Selling, general and administrative expenses | 96.4 |  |  |  |  |  |  |
Amortization of intangibles and other assets | 15.9 |  |  |  |  |  |  |
Restructuring and other charges | 1.1 |  |  |  |  |  |  |
Operating income | 11.2 |  |  |  |  |  |  |
Other income (expense): |  |  |  |  |  |  |
Other, net | (5.7) |  |  |  |  |  |  |
Earnings before income taxes | 5.5 |  |  |  |  |  |  |
Provision for income taxes | 0.6 |  |  |  |  |  |  |
Net earnings attributable to Laboratory Corporation of America Holdings | $ | 4.9 |  |  |  |  |  |  |

8

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
3. REVENUES
The Company's revenues by segment and by payers/customer groups for the three months ended March 31, 2024, and 2023, were as follows:

| For the Three Months Ended March 31, 2024 |  | For the Three Months Ended March 31, 2023
| North America |  | Europe |  | Other |  | Total |  | North America |  | Europe |  | Other |  | Total
Payer/Customer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dx |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clients | 25 | % |  | — | % |  | — | % |  | 25 | % |  | 25 | % |  | — | % |  | — | % |  | 25 | %
Patients | 10 | % |  | — | % |  | — | % |  | 10 | % |  | 9 | % |  | — | % |  | — | % |  | 9 | %
Medicare and Medicaid | 8 | % |  | — | % |  | — | % |  | 8 | % |  | 8 | % |  | — | % |  | — | % |  | 8 | %
Third party | 35 | % |  | — | % |  | — | % |  | 35 | % |  | 36 | % |  | — | % |  | — | % |  | 36 | %
Total Dx revenues by payer | 78 | % |  | — | % |  | — | % |  | 78 | % |  | 78 | % |  | — | % |  | — | % |  | 78 | %
BLS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical, biotechnology and medical device companies | 9 | % |  | 9 | % |  | 4 | % |  | 22 | % |  | 9 | % |  | 9 | % |  | 4 | % |  | 22 | %
Total revenues | 87 | % |  | 9 | % |  | 4 | % |  | 100 | % |  | 87 | % |  | 9 | % |  | 4 | % |  | 100 | %

Revenues in the U.S. were $2,654.6 (83.6%) and $2,557.4 (84.2%) for the three months ended March 31, 2024, and 2023, respectively.
Accounts Receivable, Unbilled Services and Unearned Revenue
The following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers:

| March 31, 2024 |  | December 31, 2023
Dx accounts receivable | $ | 1,260.9 |  |  | $ | 1,135.2 |
BLS accounts receivable | 857.0 |  |  | 810.8 |
Less BLS allowance for doubtful accounts | (34.2) |  |  | (32.7) |
Accounts receivable | $ | 2,083.7 |  |  | $ | 1,913.3 |
Gross unbilled services | $ | 127.8 |  |  | $ | 192.9 |
Less reserve for unbilled services | (7.4) |  |  | (7.5) |
Unbilled services | $ | 120.4 |  |  | $ | 185.4 |
Unearned revenue | $ | 377.5 |  |  | $ | 421.7 |

Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $51.0 and $52.6 for the three months ended March 31, 2024 and 2023, respectively.
Credit Loss Rollforward
The Company estimates future expected losses on accounts receivable, unbilled services and notes receivable over the remaining collection period of the instrument. The rollforward for the allowance for credit losses for the three months ended March 31, 2024, was as follows:

| Accounts Receivable |  | Unbilled Services |  | Note and Other Receivables |  | Total
Balance as of December 31, 2023 | $ | 32.7 |  |  | $ | 7.5 |  |  | $ | 0.7 |  |  | $ | 40.9 |
Plus, credit loss expense | 2.4 |  |  | — |  |  | — |  |  | 2.4 |
Less, write offs | 0.9 |  |  | 0.1 |  |  | — |  |  | 1.0 |
Balance as of March 31, 2024 | $ | 34.2 |  |  | $ | 7.4 |  |  | $ | 0.7 |  |  | $ | 42.3 |

The credit loss expense in the first three months primarily related to the collection risk from several biotech receivable balances in the first quarter.
9

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
4. BUSINESS ACQUISITIONS AND DISPOSITIONS
During the three months ended March 31, 2024, the Company acquired several businesses and related assets for cash of approximately $259.2. These acquisitions consisted of the clinical and outreach businesses of Baystate Medical Center ($116.6), Providence Medical Foundation ($54.9), and Westpac Labs, Inc. ($87.7). The preliminary purchase considerations for these acquisitions were allocated under the acquisition method of accounting to the estimated fair market value of the net assets acquired, including approximately $159.4 in identifiable intangible assets. A residual amount of tax deductible goodwill of approximately $141.7 was recorded as of March 31, 2024. The amortization period for non-compete agreements and customer list assets acquired from these businesses are 5 and 15 years, respectively. The purchase price allocations for these acquisitions have not been finalized as of March 31, 2024. The preliminary valuation of acquired assets and assumed liabilities, include the following:

| Baystate Medical Center | Providence Medical Foundation | Westpac Labs, Inc. | Amounts Acquired During the Three Months Ended March 31, 2024 | Measurement Period Adjustments for Prior Year Acquisitions During the Three Months Ended March 31, 2024 |  |
Cash and cash equivalents | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |  |  |
Inventories | — |  | — |  | 1.8 |  | 1.8 |  | — |  |  |
Property, plant and equipment | 7.2 |  | 0.9 |  | — |  | 8.1 |  | — |  |  |
Goodwill | 70.7 |  | 25.9 |  | 45.1 |  | 141.7 |  | (7.4) |  |  |
Intangible assets | 79.6 |  | 29.0 |  | 50.8 |  | 159.4 |  | 7.4 |  |  |
Other assets | — |  | — |  | — |  | — |  | — |  |  |
Total assets acquired | $ | 157.5 |  | $ | 55.8 |  | $ | 97.7 |  | $ | 311.0 |  | $ | — |  |  |
Lease liabilities | 7.2 |  | 0.9 |  | — |  | 8.1 |  | — |  |  |
Other liabilities | 3.7 |  | — |  | 10.0 |  | 13.7 |  | — |  |  |
Total liabilities acquired | 10.9 |  | 0.9 |  | 10.0 |  | 21.8 |  | — |  |  |
Net assets acquired | $ | 146.6 |  | $ | 54.9 |  | $ | 87.7 |  | $ | 289.2 |  | $ | — |  |  |
Less escrow payment made in 2023 | 30.0 |  | — |  | — |  | 30.0 |  | — |  |  |
Cash paid for acquisitions | $ | 116.6 |  | $ | 54.9 |  | $ | 87.7 |  | $ | 259.2 |  | $ | — |  |  |

During the three months ended March 31, 2023, the Company recorded several measurement period adjustments for 2022 acquisitions, relating to final valuations and deferred tax true-ups. The adjustments include the following:

|  |  |  |  | Measurement Period Adjustments During Three Months Ended March 31, 2023
Cash and cash equivalents |  |  |  |  | $ | 0.2 |
Goodwill |  |  |  |  | (30.5) |
Intangible assets |  |  |  |  | 19.9 |
Total assets acquired |  |  |  |  | $ | (10.4) |
Accrued expenses and other |  |  |  |  | (8.4) |
Deferred income taxes |  |  |  |  | (2.0) |
Total liabilities acquired |  |  |  |  | (10.4) |
Net assets acquired |  |  |  |  | $ | — |

Pro Forma Information
Had the Company's total 2024 and 2023 acquisitions been completed as of January 1, the Company's pro forma results would have been as follows:

|  |  |  | Three Months Ended March 31, |  |  |  | Three Months Ended March 31,
|  |  |  | 2024 |  |  |  |  | 2023
Revenues |  |  |  | $ | 3,191.1 |  |  |  |  |  | $ | 3,106.0 |
Net earnings from continuing operations attributable to Laboratory Corporation of America Holdings |  |  |  | $ | 227.5 |  |  |  |  |  | $ | 216.2 |

During the three months ended March 31, 2024, the Company sold the assets of its Beacon Laboratory Benefit Solutions, Inc. for $13.5 and recorded a gain of $4.9.
10

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
5. EARNINGS PER SHARE
Basic earnings per share is computed by dividing net earnings attributable to the Company by the weighted average number of shares of the Company's common stock outstanding. Diluted earnings per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the earlier of the date of issuance or the beginning of the period presented. Potentially dilutive common shares result primarily from the Company’s outstanding stock options, restricted stock awards, restricted stock units, and performance share awards.
The following represents a reconciliation of basic earnings per share to diluted earnings per share:

|  |  | Three Months Ended March 31,
|  |  |  |  | 2024 |  | 2023
|  |  |  |  |  |  |  |  |  |  |  |  | Earnings |  | Shares |  | Per Share Amount |  | Earnings |  | Shares |  | Per Share Amount
Basic earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net earnings |  |  |  |  |  |  |  |  |  |  |  |  | $ | 228.0 |  |  | 84.1 |  |  | $ | 2.71 |  |  | $ | 212.9 |  |  | 88.4 |  |  | $ | 2.41 |
Dilutive effect of employee stock options and awards |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 0.6 |  |  |  |  | — |  |  | 0.6 |  |  |
Net earnings including impact of dilutive adjustments |  |  |  |  |  |  |  |  |  |  |  |  | $ | 228.0 |  |  | 84.7 |  |  | $ | 2.69 |  |  | $ | 212.9 |  |  | 89.0 |  |  | $ | 2.39 |

Diluted earnings per share represent the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. These potential shares include dilutive stock options and unissued restricted stock awards. The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  |  |  |
Employee stock options and awards | 0.3 |  |  | 0.6 |  |  |  |  |

6. GOODWILL AND INTANGIBLE ASSETS
The changes in the carrying amount of goodwill for the three months ended March 31, 2024, were as follows:

| Dx |  |  |  | BLS |  |  |  | Total |  |
Balance as of December 31, 2023 | $ | 4,813.9 |  |  |  |  | $ | 1,328.6 |  |  |  |  | $ | 6,142.5 |  |  |
Goodwill acquired during the period | 141.7 |  |  |  |  | — |  |  |  |  | 141.7 |  |  |
Foreign currency impact and other adjustments to goodwill | (9.4) |  |  |  |  | (55.9) |  |  |  |  | (65.3) |  |  |
Balance as of March 31, 2024 | $ | 4,946.2 |  |  |  |  | $ | 1,272.7 |  |  |  |  | $ | 6,218.9 |  |  |

The Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company recognizes an impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value.
Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, the Company's business could be impacted by unfavorable changes, including those that impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions: primarily, a worsening economic environment and protracted economic downturn and related impacts, including delays in revenue from new customers; increases in customer termination activity; or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance.
The Company will continue to monitor the financial performance of, and assumptions for, its reporting units. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations.
11

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
The components of identifiable intangible assets were as follows:

| March 31, 2024 |  | December 31, 2023 |  |  |
| Gross Carrying Amount |  | Accumulated Amortization |  | Net |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net |  |  |
Customer relationships | $ | 3,945.3 |  |  | $ | (1,395.7) |  |  | $ | 2,549.6 |  |  | $ | 3,868.6 |  |  | $ | (1,367.2) |  |  | $ | 2,501.4 |  |  |  |
Patents, licenses and technology | 521.4 |  |  | (276.8) |  |  | 244.6 |  |  | 526.6 |  |  | (273.3) |  |  | 253.3 |  |  |  |
Non-compete agreements | 152.4 |  |  | (65.9) |  |  | 86.5 |  |  | 130.3 |  |  | (60.4) |  |  | 69.9 |  |  |  |
Trade name | 16.4 |  |  | (6.9) |  |  | 9.5 |  |  | 16.4 |  |  | (6.1) |  |  | 10.3 |  |  |  |
Land use right | 3.5 |  |  | (2.8) |  |  | 0.7 |  |  | 3.5 |  |  | (2.7) |  |  | 0.8 |  |  |  |
Canadian licenses | 496.0 |  |  | — |  |  | 496.0 |  |  | 498.8 |  |  | — |  |  | 498.8 |  |  |  |
Other | 14.2 |  |  | (7.0) |  |  | 7.2 |  |  | 14.2 |  |  | (6.7) |  |  | 7.5 |  |  |  |
| 5,149.2 |  |  | (1,755.1) |  |  | 3,394.1 |  |  | 5,058.4 |  |  | (1,716.4) |  |  | 3,342.0 |  |  |  |

Amortization of intangible assets for the three months ended March 31, 2024, and 2023, was $60.1 and $53.4, respectively. The amortization expense for the net carrying amount of intangible assets is estimated to be $183.3 for the remainder of fiscal 2024, $237.3 in fiscal 2025, $228.4 in fiscal 2026, $217.1 in fiscal 2027, $209.0 in fiscal 2028, and $1,737.4 thereafter.
7. DEBT
Short-term borrowings and the current portion of long-term debt at March 31, 2024, and December 31, 2023, consisted of the following:

| March 31, 2024 |  | December 31, 2023
Revolving line of credit | $ | 42.4 |  |  | $ | — |
2.30% senior notes due 2024 | 400.0 |  |  | 400.0 |
3.25% senior notes due 2024 | 600.0 |  |  | 600.0 |
3.60% senior notes due 2025 | 1,000.0 |  |  | — |
Debt issuance costs | (1.7) |  |  | (1.3) |
Current portion of note payable | 0.8 |  |  | 1.1 |
Total short-term borrowings and current portion of long-term debt | $ | 2,041.5 |  |  | $ | 999.8 |

Long-term debt at March 31, 2024, and December 31, 2023, consisted of the following:

| March 31, 2024 |  | December 31, 2023
3.60% senior notes due 2025 | — |  |  | 1,000.0 |
1.55% senior notes due 2026 | 500.0 |  |  | 500.0 |
3.60% senior notes due 2027 | 600.0 |  |  | 600.0 |
2.95% senior notes due 2029 | 650.0 |  |  | 650.0 |
2.70% senior notes due 2031 | 421.4 |  |  | 430.4 |
4.70% senior notes due 2045 | 900.0 |  |  | 900.0 |
Debt issuance costs | (24.4) |  |  | (26.3) |
Note payable | 0.6 |  |  | 0.6 |
Total long-term debt | $ | 3,047.6 |  |  | $ | 4,054.7 |

Credit Facilities
The Company maintains a senior revolving credit facility, which was amended and restated on January 13, 2023. It consists of a five-year facility in the principal amount of up to $1,000.0, with the option of increasing the facility by up to an additional $500.0, subject to the agreement of one or more new or existing lenders to provide such additional amounts and certain other customary conditions. The revolving credit facility also provides for a subfacility of up to $100.0 for swing line borrowings and a subfacility of up to $150.0 for issuances of letters of credit. The Company is required to pay a facility fee on the aggregate commitments under the revolving credit facility, at a per annum rate ranging from 0.10% to 0.225%, depending on the Company's debt ratings. The revolving credit facility is permitted to be used for general corporate purposes, including working capital, capital expenditures, funding of share repurchases and certain other payments, acquisitions, and other investments. The revolving credit facility also provides for the issuance of letters of credit without a reduction of the availability of borrowings under the facility. There was $42.4 outstanding on the Company's current revolving credit facility and $90.7 in outstanding letters of credit on the Company's subfacility as of March 31, 2024. As of March 31, 2024, the effective interest rate on the
12

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
revolving credit facility was 6.42%. The credit facility expires on April 30, 2026.
Under the revolving credit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers, and the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants in the revolving credit facility at March 31, 2024, and expects that it will remain in compliance with its existing debt covenants for the next twelve months.
8. PREFERRED STOCK AND COMMON SHAREHOLDERS’ EQUITY
The Company is authorized to issue up to 265.0 shares of common stock, par value $0.10 per share. The Company is authorized to issue up to 30.0 shares of preferred stock, par value $0.10 per share. There were no preferred shares outstanding as of March 31, 2024, and December 31, 2023.
The changes in common shares issued are summarized below:

| Issued and Outstanding |  |  |  |
Common shares at December 31, 2023 | 83.9 |  |  |  |  |
Shares issued under employee stock plans | 0.4 |  |  |  |  |
Common shares at March 31, 2024 | 84.3 |  |  |  |  |

Share Repurchase Program
When the Company repurchases shares of Common Stock, the amount paid to repurchase the shares in excess of the par or stated value is allocated to additional paid-in-capital unless subject to limitation or the balance in additional paid-in-capital is exhausted. Remaining amounts are recognized as a reduction in retained earnings.
As of March 31, 2024, the Company had outstanding authorization from the board of directors to purchase up to $531.5 of the Company's common stock.
Dividends
For the three months ended March 31, 2024, the Company paid $62.1 in common stock dividends. On April 11, 2024, the Company announced a cash dividend of $0.72 per share of common stock for the first quarter, or approximately $61.4 in the aggregate. The dividend will be payable on June 12, 2024, to stockholders of record of all issued and outstanding shares of common stock as of the close of business on May 28, 2024. The declaration and payment of any future dividends will be at the discretion of the Company's board of directors.
Accumulated Other Comprehensive Earnings (Loss)
The components of accumulated other comprehensive earnings (loss) were as follows:

| Foreign Currency Translation Adjustments |  | Net Benefit Plan Adjustments |  |  |  | Accumulated Other Comprehensive Earnings (Loss)
Balance as of December 31, 2023 | $ | (47.6) |  |  | $ | (11.7) |  |  |  |  | $ | (59.3) |
Current year adjustments | (124.3) |  |  | (1.5) |  |  |  |  | (125.8) |
Amounts reclassified from accumulated other comprehensive income | — |  |  | (0.9) |  |  |  |  | (0.9) |
Tax effect of adjustments | — |  |  | 0.6 |  |  |  |  | 0.6 |
Balance as of March 31, 2024 | $ | (171.9) |  |  | $ | (13.5) |  |  |  |  | $ | (185.4) |

9. COMMITMENTS AND CONTINGENCIES
The Company is involved from time to time in various claims and legal actions, including arbitrations, class actions, and other litigation (including those described in more detail below), arising in the ordinary course of business. Some of these actions involve claims that are substantial in amount. These matters include, but are not limited to, intellectual property disputes, commercial and contract disputes, professional liability claims, employee-related matters, transaction-related disputes, securities and corporate law matters, and inquiries, including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payers and managed care organizations (MCOs) reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company receives civil investigative demands or other inquiries from various governmental bodies in the ordinary course of its business. Such inquiries can relate to the Company or other parties, including physicians and other health care providers. The Company works cooperatively to respond to appropriate requests for information.
13

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
The Company also is named from time to time in suits brought under the qui tam provisions of the False Claims Act and comparable state laws. These suits typically allege that the Company has made false statements and/or certifications in connection with claims for payment from U.S. federal or state healthcare programs. The suits may remain under seal (hence, unknown to the Company) for some time while the government decides whether to intervene on behalf of the qui tam plaintiff. Such claims are an inevitable part of doing business in the healthcare field today.
The Company believes that it is in compliance in all material respects with all statutes, regulations, and other requirements applicable to its commercial laboratory operations and biopharma laboratory services. These industries are, however, subject to extensive regulation, and the courts have not interpreted many of the applicable statutes and regulations. Therefore, the applicable statutes and regulations could be interpreted or applied by a prosecutorial, regulatory, or judicial authority in a manner that would adversely affect the Company. Potential sanctions for violation of these statutes and regulations include significant civil and criminal penalties, fines, the loss of various licenses, certificates and authorizations, additional liabilities from third-party claims, and/or exclusion from participation in government programs.
Many of the current claims and legal actions against the Company are in preliminary stages, and many of these cases seek an indeterminate amount of damages. The Company records an aggregate legal reserve, which is determined using calculations based on historical loss rates and assessment of trends experienced in settlements and defense costs. In accordance with FASB Accounting Standards Codification Topic 450 “Contingencies,” the Company establishes reserves for judicial, regulatory, and arbitration matters outside the aggregate legal reserve if and when those matters present loss contingencies that are both probable and reasonably estimable. When loss contingencies are not both probable and reasonably estimable, the Company does not establish separate reserves.
The Company is unable to estimate a range of reasonably probable loss for the proceedings described in more detail below in which damages either have not been specified or, in the Company's judgment, are unsupported and/or exaggerated and (i) the proceedings are in early stages, (ii) there is uncertainty as to the outcome of pending appeals or motions, (iii) there are significant factual issues to be resolved, and/or (iv) there are novel legal issues to be presented. For these proceedings, however, the Company does not believe, based on currently available information, that the adverse outcomes are probable and reasonably estimable, and it does not believe they will have a material adverse effect on the Company's financial statements.
The Company has received various subpoenas and other civil investigative demands related to Medicaid billing. In October 2013, the Company received a Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company cooperated with this request. On October 5, 2018, the Company received a second Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company cooperated with this request. On January 26, 2021, the Company was notified that a qui tam Petition was pending under seal in the District Court, 250th Judicial District, Travis County, Texas, and that the State of Texas had intervened. On April 14, 2021, the Petition was unsealed. The Petition alleges that the Company submitted claims for reimbursement to Texas Medicaid that were higher than permitted under Texas Medicaid’s alleged “best price” regulations, and that the Company offered remuneration to Texas health care providers in the form of discounted pricing for certain laboratory testing services in exchange for the providers’ referral of Texas Medicaid business to the Company. The Petition seeks actual and double damages and civil penalties, as well as recovery of costs, attorney's fees, and legal expenses. On August 1, 2022, the District Court entered an order granting the Company's Motion for Partial Summary Judgment with respect to the claim that the Company submitted claims for reimbursement to Texas Medicaid that were higher than permitted under Texas Medicaid's alleged “best price” regulations. Plaintiffs filed a Notice of Non-Suit and Motion for Entry of Final Judgment and, on November 11, 2022, the court entered a Judgment. Plaintiffs filed a Notice of Appeal with respect to the court's order granting the Company's Motion for Partial Summary Judgment, referenced above. The Company will vigorously defend the lawsuit.
On August 31, 2015, the Company was served with a putative class action lawsuit, Patty Davis v. Laboratory Corporation of America, et al., filed in the Circuit Court of the Thirteenth Judicial Circuit for Hillsborough County, Florida. The complaint alleges that the Company violated the Florida Consumer Collection Practices Act by billing patients who were collecting benefits under the Workers' Compensation Statutes. The lawsuit seeks injunctive relief and actual and statutory damages, as well as recovery of attorney's fees and legal expenses. In April 2017, the Circuit Court granted the Company’s Motion for Judgment on the Pleadings. The Plaintiff appealed the Circuit Court’s ruling to the Florida Second District Court of Appeal. On October 16, 2019, the Florida Second District Court of Appeal reversed the Circuit Court’s dismissal, but certified a controlling issue of Florida law to the Florida Supreme Court. On February 17, 2020, the Florida Supreme Court accepted jurisdiction of the lawsuit. The court held oral arguments on December 9, 2020. On May 26, 2022, the Florida Supreme Court issued an opinion approving the result of the Florida Second District Court of Appeal in favor of the Plaintiff. The Company will vigorously defend the lawsuit.
14

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
On December 29, 2021, the Company was served with a putative class action lawsuit, Nathaniel J. Nolan, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Middle District of North Carolina. The complaint alleges that the Company's patient acknowledgement of estimated financial responsibility form is misleading. The lawsuit seeks a declaratory judgment under the consumer protection laws of Nevada and Florida that the form is materially misleading and deceptive, an injunction barring the use of the form, damages on behalf of an alleged class, and attorney's fees and expenses. On February 28, 2022, the Company filed a Motion to Dismiss all claims. On February 13, 2023, the court entered an order granting the Company's Motion to Dismiss. On March 13, 2023, Plaintiffs filed a Notice of Appeal. On April 10, 2024, the U.S. Court of Appeals for the Fourth Circuit issued an order affirming in part, reversing in part, and remanding the case to the District Court for further proceedings. The Company will vigorously defend the lawsuit.
On April 1, 2019, Covance Research Products was served with a Grand Jury Subpoena issued by the Department of Justice (DOJ) in Miami, Florida requiring the production of documents related to the importation into the United States of live non-human primate shipments originating from or transiting through China, Cambodia, and/or Vietnam from April 1, 2014 through March 28, 2019. The Company is cooperating with the DOJ.
On May 14, 2019, Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (AMCA), an external collection agency, notified the Company about a security incident AMCA experienced that may have involved certain personal information about some of the Company’s patients (the AMCA Incident). The Company referred patient balances to AMCA only when direct collection efforts were unsuccessful. The Company’s systems were not impacted by the AMCA Incident. Upon learning of the AMCA Incident, the Company promptly stopped sending new collection requests to AMCA and stopped AMCA from continuing to work on any pending collection requests from the Company. AMCA informed the Company that it appeared that an unauthorized user had access to AMCA’s system between August 1, 2018, and March 30, 2019, and that AMCA could not rule out the possibility that personal information on AMCA’s system was at risk during that time period. Information on AMCA’s affected system from the Company may have included name, address, and balance information for the patient and person responsible for payment, along with the patient’s phone number, date of birth, referring physician, and date of service. The Company was later informed by AMCA that health insurance information may have been included for some individuals, and because some insurance carriers utilize the Social Security Number as a subscriber identification number, the Social Security Number for some individuals may also have been affected. No ordered tests, laboratory test results, or diagnostic information from the Company were in the AMCA affected system. The Company notified individuals for whom it had a valid mailing address. For the individuals whose Social Security Number was affected, the notice included an offer to enroll in credit monitoring and identity protection services that was provided free of charge for 24 months.
Twenty-three putative class action lawsuits were filed against the Company related to the AMCA Incident in various U.S. District Courts. Numerous similar lawsuits have been filed against other health care providers who used AMCA. These lawsuits were consolidated into a multidistrict litigation in the District of New Jersey. On November 15, 2019, the Plaintiffs filed a Consolidated Class Action Complaint in the U.S. District Court of New Jersey. The consolidated Complaint generally alleged that the Company did not adequately protect its patients’ data and failed to timely notify those patients of the AMCA Incident. The Complaint asserted various causes of action, including but not limited to negligence, breach of implied contract, unjust enrichment, and the violation of state data protection statutes. The Complaint sought damages on behalf of a class of all affected Company customers. On January 22, 2020, the Company filed Motions to Dismiss all claims. On December 16, 2021, the court granted in part and denied in part the Company's Motion to Dismiss. On March 31, 2022, the Plaintiffs filed an Amended Complaint alleging claims for negligence, negligence per se, breach of confidence, invasion of privacy, and various state statutory claims, including a claim under the California Confidentiality of Medical Information Act. The Company filed a Motion to Dismiss certain claims of the Amended Complaint. On May 5, 2023, the court granted in part and denied in part the Company's Motion to Dismiss. The Company will vigorously defend the remaining claims in the multi-district litigation.
The Company was served with a shareholder derivative lawsuit, Raymond Eugenio, Derivatively on Behalf of Nominal Defendant, Laboratory Corporation of America Holdings v. Lance Berberian, et al., filed in the Court of Chancery of the State of Delaware on April 23, 2020. The complaint asserts derivative claims on the Company’s behalf against the Company’s board of directors and certain executive officers. The complaint generally alleges that the defendants failed to ensure that the Company utilized proper cybersecurity safeguards and failed to implement a sufficient response to data security incidents, including the AMCA Incident. The complaint asserts derivative claims for breach of fiduciary duty and seeks relief including damages, certain disclosures, and certain changes to the Company’s internal governance practices. On June 2, 2020, the Company filed a Motion to Stay the lawsuit due to its overlap with the multi-district litigation referenced above. On July 2, 2020, the Company filed a Motion to Dismiss. On July 14, 2020, the court entered an order staying the lawsuit pending the resolution of the multi-district litigation. The Company will vigorously defend the lawsuit.
15

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
Certain governmental entities have requested information from the Company related to the AMCA Incident. The Company received a request for information from the Office for Civil Rights (OCR) of the Department of Health and Human Services. On April 28, 2020, OCR notified the Company of the closure of its inquiry. The Company has also received requests from a multi-state group of state Attorneys General and is cooperating with these requests for information.
On January 31, 2020, the Company was served with a putative class action lawsuit, Luke Davis and Julian Vargas, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Central District of California. The lawsuit alleges that visually impaired patients are unable to use the Company's touchscreen kiosks at Company patient service centers in violation of the Americans with Disabilities Act and similar California statutes. The lawsuit seeks statutory damages, injunctive relief, and attorney's fees and costs. On March 20, 2020, the Company filed a Motion to Dismiss Plaintiffs' Complaint and to Strike Class Allegations. In August 2020, the Plaintiffs filed an Amended Complaint. On April 26, 2021, the Plaintiffs and the Company each filed Motions for Summary Judgment and the Plaintiffs filed a Motion for Class Certification. On May 23, 2022, the court entered an order granting Plaintiffs’ Motion for Class Certification. On June 6, 2022, the Company filed a Petition for Permission to Appeal the Order Granting Class Certification with the U.S. Court of Appeals for the Ninth Circuit. On September 22, 2022, the Ninth Circuit granted the Company's Petition for Permission to Appeal the Order Granting Class Certification. On February 8, 2024, the Ninth Circuit affirmed the trial court’s decision to certify both a California damages class and a nationwide injunctive class. On March 25, 2024, the Company filed a Petition for Rehearing En Banc with the Ninth Circuit. On April 18, 2024, the Ninth Circuit denied the Petition for Rehearing En Banc. The Company will vigorously defend the lawsuit.
On October 16, 2020, Ravgen Inc. filed a patent infringement lawsuit, Ravgen Inc. v. Laboratory Corporation of America Holdings, in the U.S. District Court for the Western District of Texas, alleging infringement of two Ravgen-owned U.S. patents. The lawsuit seeks monetary damages, enhancement of those damages for willfulness, and recovery of attorney’s fees and costs. On September 28, 2022, a jury rendered a verdict in favor of the Plaintiff on the remaining patent at issue, finding that the Company willfully infringed Ravgen's patent, and awarded damages of $272.0. Plaintiff filed post-trial motions seeking enhanced damages of up to $817.0 based on the finding of willfulness, as well as attorney's fees and costs. On May 12, 2023, the court issued an order granting Plaintiff's motion in part and awarding enhanced damages of $100.0. The Company strongly disagrees with the verdict, based on a number of legal factors, and will vigorously defend the lawsuit through the appeal process. On June 4, 2021, the Company also instituted proceedings before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office challenging the validity of the Ravgen patent at issue in the trial. In November 2022, the Patent Trial and Appeal Board issued a decision upholding the validity of the Ravgen patent, and the Company has filed an appeal of this decision.
On May 14, 2020, the Company was served with a putative class action lawsuit, Jose Bermejo v. Laboratory Corporation of America (Bermejo I) filed in the Superior Court of California, County of Los Angeles Central District, alleging that certain non-exempt California-based employees were not properly compensated for driving time or properly paid wages upon termination of employment. The Plaintiff asserts these actions violate various California Labor Code provisions and Section 17200 of the Business and Professional Code. The lawsuit seeks monetary damages, civil penalties, and recovery of attorney’s fees and costs. On June 15, 2020, the lawsuit was removed to the U.S. District Court for the Central District of California. On June 16, 2020, the Company was served with a Private Attorney General Act lawsuit by the same plaintiff in Jose Bermejo v. Laboratory Corporation of America (Bermejo II), filed in the Superior Court of California, County of Los Angeles Central District, alleging that certain Company practices violated California Labor Code penalty provisions related to unpaid and minimum wages, unpaid overtime, unpaid meal and rest break premiums, untimely payment of wages following separation of employment, failure to maintain accurate pay records, and non-reimbursement of business expenses. The second lawsuit seeks to recover civil penalties and recovery of attorney's fees and costs. On October 28, 2020, the court issued an order staying proceedings in Bermejo II pending resolution of Bermejo I. The second lawsuit seeks to recover civil penalties and recovery of attorney's fees and costs. On February 24, 2022, the parties entered into a Memorandum of Understanding of the terms of a settlement of the Bermejo I and Bermejo II lawsuits. The court granted preliminary approval of the parties’ settlement agreement of the Bermejo I lawsuit on March 17, 2023, and of the Bermejo II lawsuit on November 29, 2023. The settlement funds for the Bermejo I and Bermejo II settlements have been transferred to a claims administrator for processing. Once the claims administration is completed, the parties will seek final settlement approval from the court.
On June 14, 2021, a single plaintiff filed a Private Attorney General Act lawsuit, Becker v. Laboratory Corporation of America, in the Superior Court of California, County of Orange, alleging various violations of the California Labor Code, including that the Plaintiff was not properly compensated for work and overtime hours, not properly paid meal and rest break premiums, not reimbursed for certain business-related expenses, and received inaccurate wage statements. The lawsuit seeks monetary damages, civil penalties, and recovery of attorney’s fees and costs. A settlement of the Bermejo I and Bermejo II lawsuits, if approved by the court, will resolve the Becker lawsuit.
16

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
On November 23, 2021, the Company was served with a single plaintiff Private Attorney General Act lawsuit, Poole v. Laboratory Corporation of America, filed in the Superior Court of California, County of Kern, alleging various violations of the California Labor Code, including that Plaintiff was not properly paid wages owed, not properly paid meal and rest break premiums, not reimbursed for certain business related expenses, and other allegations including the untimely payment of wages and receipt of inaccurate wage statements. The lawsuit seeks monetary damages, civil penalties, and recovery of attorney's fees and costs. The case was removed to the U.S. District Court for the Eastern District of California. A settlement of the Bermejo I and Bermejo II lawsuits, if approved by the court, will resolve the portion of the Poole lawsuit relating to service representatives and senior service representatives.
On October 5, 2020, the Company was served with a putative class action lawsuit, Williams v. LabCorp Employer Services, Inc. et al., filed in the Superior Court of California, County of Los Angeles, alleging that certain non-exempt California-based employees were not properly compensated for work and overtime hours, not properly paid meal and rest break premiums, not reimbursed for certain business-related expenses, not properly paid for driving or wait times, and received inaccurate wage statements. The Plaintiff also asserts claims for unfair competition under Section 17200 of the Business and Professional Code. On November 4, 2020, the lawsuit was removed to the U.S. District Court for the Central District of California. The lawsuit seeks monetary damages, liquidated damages, civil penalties, and recovery of attorney's fees and costs. On June 24, 2021, the District Court remanded the case to the Superior Court of California, County of Los Angeles on the grounds that potential damages did not meet the Class Action Fairness Act (CAFA), 28 U.S.C. § 1332(d), jurisdictional threshold. The parties entered into a settlement agreement which received court preliminary approval on December 13, 2023. Settlement proceeds were transferred to the settlement fund administrator in January 2024 and have been distributed by the settlement fund administrator. A case review is scheduled by the court for September 13, 2024, at which time the court is expected to sua sponte dismiss the lawsuit given its resolution by settlement.
On June 7, 2023, the Company was served with a putative class action lawsuit, Connie Howard, Yadira Yazmin Hernandez, and Deborah Reynolds, et al. v. Laboratory Corporation of America, Laboratory Corporation of America Holdings, and Meta Platforms, Inc., filed in the U.S. District Court for the Northern District of California, alleging that the Company’s website includes a tracking code created by Meta, known as the Meta Pixel, that sent information related to Plaintiffs and their online activities to Meta. Plaintiffs assert claims against the Company under California and Pennsylvania law and seek to represent classes of all persons in California, or in Pennsylvania, who allegedly entered search terms into the Company’s website and who used Facebook during a time that Plaintiffs allege the Meta Pixel was active on the Company’s website. Plaintiffs seek an injunction, damages, attorneys’ fees, and costs. On August 23, 2023, the Company filed a Motion to Dismiss. On September 5, 2023, the lawsuit was transferred to the U.S. District Court for the Middle District of North Carolina. On September 9, 2023, Plaintiffs filed an Amended Complaint. Among other things, the Amended Complaint contains allegations that in addition to the Meta Pixel, the Company's website uses Google Analytics and other online tracking technologies. The Company will vigorously defend the lawsuit.
On August 14, 2020, the Company was served with a Subpoena Duces Tecum issued by the State of Colorado Office of the Attorney General requiring the production of documents related to urine drug testing in all states. The Company is cooperating with this request.
On February 7, 2022, the Company was served with a Subpoena Duces Tecum issued by the DOJ in Camden, New Jersey requiring the production of documents related to non-invasive prenatal screening tests. The Company is cooperating with the DOJ.
On June 27, 2022, the Company was served with a Subpoena Duces Tecum issued by the DOJ in Boston, Massachusetts requiring the production of documents related to urine drug testing. The Company is cooperating with the DOJ.
In April 2023, the Company received Civil Investigative Demands issued by the DOJ in Washington, D.C. requiring the production of information related to the Medicare billing rule regarding reimbursement for laboratory testing performed for hospital patients. The Company is cooperating with the DOJ.
On February 13, 2024, a putative class action lawsuit, Michael Wiggins and Teri Stevens v. Laboratory Corporation of America Holdings, was filed in the U.S. District Court for the Eastern District of Pennsylvania, alleging that the Company’s website includes a computer code created by Google that sent information to Google related to Plaintiffs and their online activities. Plaintiffs assert statutory and common law claims against the Company and seek to represent a class of all persons whose health information was allegedly shared with Google from the Company’s website before March 8, 2023. Plaintiffs seek an injunction, damages, attorneys’ fees, and costs. On April 12, 2024, the Company filed a Motion to Compel Arbitration and Stay Proceedings. The Company will vigorously defend the lawsuit.
17

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
There are various other pending legal proceedings involving the Company including, but not limited to, additional employment-related lawsuits, professional liability lawsuits, and commercial lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, the likelihood of loss is remote and any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations, or cash flows, either individually or in the aggregate.
Under the Company's present insurance programs, coverage is obtained for catastrophic exposure as well as those risks required to be insured by law or contract. The Company is responsible for the uninsured portion of losses related primarily to general, professional and vehicle liability, certain medical costs and workers' compensation. The self-insured retentions are on a per-occurrence basis without any aggregate annual limit. Provisions for losses expected under these programs are recorded based upon the Company's estimates of the aggregated liability of claims incurred.
10. FAIR VALUE MEASUREMENTS
The Company’s population of financial assets and liabilities subject to fair value measurements as of March 31, 2024, and December 31, 2023, was as follows:

|  |  |  |  | Fair Value Measurements as of
|  |  |  |  | March 31, 2024
| Balance Sheet |  | Fair Value as of |  | Using Fair Value Hierarchy
| Classification |  | March 31, 2024 |  | Level 1 |  | Level 2 |  | Level 3
Noncontrolling interest put | Noncontrolling interest |  | $ | 15.2 |  |  | $ | — |  |  | $ | 15.2 |  |  | $ | — |
Cross currency swaps | Other liabilities |  | 92.0 |  |  | — |  |  | 92.0 |  |  | — |
Interest rate swaps | Other liabilities |  | 78.6 |  |  | — |  |  | 78.6 |  |  | — |
Cash surrender value of life insurance policies | Other assets, net |  | 94.1 |  |  | — |  |  | 94.1 |  |  | — |
Deferred compensation asset | Other assets, net |  | 28.3 |  |  | — |  |  | 28.3 |  |  | — |
Deferred compensation liability | Other liabilities |  | 121.0 |  |  | — |  |  | 121.0 |  |  | — |
Contingent consideration | Accrued expenses and other; Other liabilities |  | 79.8 |  |  | — |  |  | — |  |  | 79.8 |

|  |  |  |  | Fair Value Measurements as of
|  |  |  |  | December 31, 2023
| Balance Sheet |  | Fair Value as of |  | Using Fair Value Hierarchy
| Classification |  | December 31, 2023 |  | Level 1 |  | Level 2 |  | Level 3
Noncontrolling interest put | Noncontrolling interest |  | $ | 15.5 |  |  | $ | — |  |  | $ | 15.5 |  |  | $ | — |
Cross currency swaps | Accrued expenses and other; Other liabilities |  | 109.0 |  |  | — |  |  | 109.0 |  |  | — |
Interest rate swaps | Other liabilities, net |  | 69.6 |  |  | — |  |  | 69.6 |  |  | — |
Cash surrender value of life insurance policies | Other assets, net |  | 95.4 |  |  | — |  |  | 95.4 |  |  | — |
Deferred compensation asset | Other assets, net |  | 21.1 |  |  | — |  |  | 21.1 |  |  | — |
Deferred compensation liability | Other liabilities |  | 107.4 |  |  | — |  |  | 107.4 |  |  | — |
Contingent consideration | Accrued expenses and other; Other liabilities |  | 66.1 |  |  | — |  |  | — |  |  | 66.1 |

Fair Value Measurement of Level 3 Liabilities |  | Contingent Consideration
Balance at December 31, 2023 |  | $ | 66.1 |
Additions |  | 13.7 |
Balance as of March 31, 2024 |  | $ | 79.8 |

The Company has a noncontrolling interest put related to its Ontario subsidiary that has been classified as mezzanine equity in the Company’s condensed consolidated balance sheets. The noncontrolling interest put is valued at its contractually determined value, which approximates fair value.
The Company offers certain employees the opportunity to participate in an employee-funded deferred compensation plan (DCP). A participant's deferrals are allocated by the participant to one or more of multiple measurement funds, which are indexed to externally managed funds. From time to time, to offset the cost of the growth in the participant's investment accounts, the Company purchases life insurance policies, with the Company named as beneficiary of the policies. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying
18

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)
investments, which are typically invested in a similar manner to the participant's allocations. Changes in the fair value of the DCP obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the DCP obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.
Contingent accrued earn-out business acquisition consideration liabilities are measured at fair value using Level 3 valuations. These contingent consideration liabilities were recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration payable can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are not observable in the market, they are categorized as Level 3.
The carrying amounts of cash and cash equivalents, accounts receivable, income taxes receivable, and accounts payable are considered to be representative of their respective fair values due to their short-term nature. The fair market value of the senior notes, based on market pricing, was approximately $4,829.2 and $4,850.4 as of March 31, 2024, and December 31, 2023, respectively. The Company's note and debt instruments are classified as Level 2 instruments, as the fair market values of these instruments are determined using other observable inputs.
Cross-Currency Swap
During the fourth quarter of 2018, the Company entered into U.S. Dollar (USD) to Swiss Franc cross-currency swap agreements with an aggregate notional value of $600.0. During the second quarter of 2022, the Company terminated $300.0 of those cross-currency swap agreements and entered into new USD to Swiss Franc cross-currency swap agreements with an aggregate notional value of $300.0 that mature in 2024. During the first quarter of 2024, the Company terminated its 2024 and 2025 USD to Swiss Franc cross currency swaps and entered into two new swaps, each with a notional value of $300.0 and maturity dates of 2031 and 2034, respectively. These cross currency swaps are included in accrued expenses and other and other long-term liabilities as appropriate with an aggregate fair value of $92.0 and $109.0 as of March 31, 2024 and December 31, 2023, respectively. Changes in the fair value of the cross-currency swaps are charged or credited through accumulated other comprehensive income in the Consolidated Balance Sheet until the hedged item is recognized in earnings. The cumulative amount of the fair value hedging adjustments are recognized as currency translation within the Consolidated Statement of Comprehensive Earnings.
11. SUPPLEMENTAL CASH FLOW INFORMATION

| Three Months Ended March 31,
| 2024 |  | 2023
Cash paid during period for: |  |  |
Interest | $ | 71.6 |  |  | $ | 70.5 |
Income taxes, net of refunds | 21.5 |  |  | 28.4 |
Disclosure of non-cash financing and investing activities: |  |  |
Change in accrued property, plant, and equipment | (12.2) |  |  | (3.9) |

12. BUSINESS SEGMENT INFORMATION
The following table is a summary of segment information for the three months ended March 31, 2024, and 2023. The “management approach” has been used to present the following segment information. This approach is based upon the way the management of the Company organizes segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Company’s chief executive officer has been identified as the CODM.
The prior period has been conformed to the new segment presentation as a result of the spin-off of Fortrea.
Segment asset information is not presented because it is not used by the CODM at the segment level. The Corporate costs not allocated to segments include the costs of centralized functions, other charges such as acquisition expenses, spin-off costs, remaining unallocated costs of the CDCS business, and COVID-19 related costs unrelated to the segment. Centralized functions include corporate governance, executive management and related human resources, finance, legal, risk management, and information technology functions.
19

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

|  |  |  | Three Months Ended March 31,
|  |  |  |  |  | 2024 |  | 2023
Revenues: |  |  |  |  |  |  |  |
Dx |  |  |  |  |  | $ | 2,479.7 |  |  | $ | 2,382.8 |
BLS |  |  |  |  |  | 710.9 |  |  | 661.3 |
Intercompany eliminations and other |  |  |  |  |  | (14.0) |  |  | (6.3) |
Total revenues |  |  |  |  |  | $ | 3,176.6 |  |  | $ | 3,037.8 |
Operating Earnings: |  |  |  |  |  |  |  |
Dx segment operating income |  |  |  |  |  | $ | 417.9 |  |  | $ | 441.5 |
BLS segment operating income |  |  |  |  |  | 99.9 |  |  | 73.6 |
Segment operating income |  |  |  |  |  | 517.8 |  |  | 515.1 |
General corporate and unallocated expenses |  |  |  |  |  | (128.9) |  |  | (122.2) |
Amortization of intangibles and other assets |  |  |  |  |  | (60.1) |  |  | (53.4) |
Restructuring and other charges |  |  |  |  |  | (5.0) |  |  | (7.5) |
Goodwill and other asset impairments |  |  |  |  |  | (2.5) |  |  | (2.2) |
Total operating income |  |  |  |  |  | $ | 321.3 |  |  | $ | 329.8 |

13. SUBSEQUENT EVENTS
On April 24, 2024, the Company announced that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024. The purchase price for the transaction is $239.0. The transaction is anticipated to close in third quarter of 2024, subject to customary closing conditions for a transaction of this type, including applicable regulatory approvals. Through this transaction, the Company would acquire assets being auctioned through a voluntary bankruptcy protection process.
20

INDEX
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FORWARD-LOOKING STATEMENTS
The Company has made in this report, and from time to time may otherwise make in its public filings, press releases, and discussions by Company management, forward-looking statements concerning the Company’s operations, performance, and financial condition, as well as its strategic objectives. Some of these forward-looking statements relate to future events and expectations and can be identified by the use of forward-looking words such as “believes”, “expects”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates”, or “anticipates” or the negative of those words or other comparable terminology. Such forward-looking statements speak only as of the time they are made and are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein, including in the “Summary of Material Risks” and “Risk Factors” section of the Annual Report on Form 10-K, and in the Company’s other public filings, press releases, and discussions with Company management, including:
1.changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in the U.S. healthcare system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of the U.S. Protecting Access to Medicare Act of 2014 (PAMA);
2.significant monetary damages, fines, penalties, assessments, refunds, repayments, damage to the Company’s reputation, unanticipated compliance expenditures, and/or exclusion or debarment from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business;
3.significant fines, penalties, costs, unanticipated compliance expenditures, and/or damage to the Company’s reputation arising from the failure to comply with applicable privacy and security laws and regulations, including the U.S. Health Insurance Portability and Accountability Act of 1996, the U.S. Health Information Technology for Economic and Clinical Health Act, the European Union's General Data Protection Regulation and similar laws and regulations in jurisdictions in which the Company conducts business;
4.loss or suspension of a license or imposition of fines or penalties under, or future changes in, or interpretations of applicable licensing laws or regulations regarding the operation of clinical laboratories, the development and commercialization of laboratory-developed tests (LDTs), and the delivery of clinical laboratory test results, including, but not limited to, the U.S. Clinical Laboratory Improvement Act of 1967, the U.S. Clinical Laboratory Improvement Amendments of 1988, the European Union In Vitro Diagnostics Regulation, and similar laws and regulations in jurisdictions in which the Company conducts business;
5.penalties or loss of license arising from the failure to comply with applicable occupational and workplace safety laws and regulations, including the U.S. Occupational Safety and Health Administration requirements, the U.S. Needlestick Safety and Prevention Act, and similar laws and regulations in jurisdictions in which the Company conducts business;
6.fines, unanticipated compliance expenditures, suspension of manufacturing, enforcement actions, damage to the Company's reputation, injunctions, or criminal prosecution arising from failure to maintain compliance with current good manufacturing practice regulations and similar requirements of various regulatory agencies in jurisdictions in which the Company conducts business;
7.sanctions or other remedies, including fines, unanticipated compliance expenditures, enforcement actions, injunctions or criminal prosecution arising from failure to comply with the Animal Welfare Act or applicable national, state and local laws and regulations in jurisdictions in which the Company conducts business;
8.changes in testing guidelines or recommendations by government agencies, medical specialty societies, and other authoritative bodies affecting the development, validation, approval, clearance, commercialization, or utilization of laboratory tests;
9.changes in applicable government regulations or policies affecting the approval, availability of, and the selling and marketing of diagnostic tests, including LDTs, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S. Food and Drug Administration, the U.S. Department of Agriculture, the Medicine and Healthcare products Regulatory Agency in the United Kingdom, the National Medical Products Administration in China, the Pharmaceutical and Medical Devices Agency in Japan, the
21

INDEX
European Medicines Agency in the European Union, and similar regulations and policies of agencies in other jurisdictions in which the Company conducts business;
10.changes in government regulations or reimbursement pertaining to the pharmaceutical, biotechnology and medical device and diagnostic industries, changes in reimbursement of pharmaceutical products, or reduced spending on research and development by pharmaceutical, biotechnology and medical device and diagnostic customers;
11.liabilities that result from the failure to comply with corporate governance requirements;
12.increased competition, including price competition, potential reduction in rates in response to price transparency initiatives and consumerism, competitive bidding and/or changes or reductions to fee schedules, and competition from companies that do not comply with existing applicable laws or regulations or otherwise disregard compliance standards in the industry;
13.changes in payer mix or payment structure or process, including insurance carrier participation in health insurance exchanges, an increase in capitated reimbursement mechanisms, the impact of clearinghouses on the claims reimbursement process, the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing, and adverse changes in payer reimbursement or payer coverage policies (implemented directly or through a third-party utilization management organization) related to specific diagnostic tests, categories of testing or testing methodologies;
14.failure to retain or attract business from managed care organizations (MCOs) as a result of changes in business models, including risk based or network approaches, out-sourced laboratory network management or utilization management companies, or other changes in strategy or business models by MCOs;
15.failure to obtain and retain new customers, an unfavorable change in the mix of testing services ordered, or a reduction in tests ordered, specimens submitted, or services requested by existing customers, and delays in payments from customers;
16.consolidation and convergence of customers, competitors, and suppliers, potentially causing material shifts in insourcing, utilization, pricing, reimbursement and supply chain access;
17.failure to invest in or effectively develop and deploy new systems, system modifications or enhancements required in response to evolving market, business, and customer trends and needs;
18.customers choosing to insource services that are or could be purchased from the Company;
19.failure to identify, successfully close and effectively integrate and/or manage acquisitions of new businesses or failure to maintain key customers and/or employees as a result of uncertainty surrounding the integration of acquisitions;
20.inability to achieve the expected benefits and synergies of newly-acquired businesses, including due to items not discovered in the due diligence process, and the impact on the Company’s cash position, levels of indebtedness and stock price;
21.termination, loss, delay, reduction in scope or increased costs of contracts, including large contracts and multiple contracts;
22.liability arising from errors or omissions in the performance of testing and other services or other contractual arrangements;
23.changes or disruption in the provision or transportation of services or supplies provided by third parties; or their termination for failure to follow the Company’s performance standards and requirements;
24.damage or disruption to the Company’s facilities;
25.damage to the Company’s reputation, loss of business, or other harm from acts of animal rights activists or potential harm and/or liability arising from animal research activities;
26.adverse results in litigation matters;
27.inability to attract, retain, and develop experienced and qualified personnel or the loss of significant personnel as a result of illness, increased competition for talent, wage growth, or other market factors beyond the Company’s control;
28.failure to develop or acquire licenses for new or improved technologies, such as point-of-care testing, mobile health technologies, and digital pathology, or potential use of new technologies by customers and/or consumers to perform their own tests;
29.substantial costs arising from the inability to commercialize newly licensed tests or technologies or to obtain appropriate coverage or reimbursement for such tests;
22

INDEX
30.failure to obtain, maintain, and enforce intellectual property rights for protection of the Company’s products and services and defend against challenges to those rights;
31.scope, validity, and enforceability of patents and other proprietary rights held by third parties that may impact the Company’s ability to develop, perform, or market the Company's products or services or operate its business;
32.business interruption, receivables impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions or inventory obsolescence, increases in material cost or other operating costs, or other impacts on the business due to natural disasters, including adverse weather, fires and earthquakes; geopolitical crises, including terrorism and war; public health crises and disease epidemics and pandemics, including, but not limited to the continued impact of COVID-19; and other events beyond the Company’s control;
33.discontinuation or recalls of existing testing products;
34.a failure in the Company’s information technology systems, including with respect to testing turnaround time and billing processes, the failure of the Company or its third-party suppliers and vendors to maintain the security of business information or systems or to protect against cybersecurity incidents such as denial of service attacks, malware, ransomware, and computer viruses, delays or failures in the development and implementation of the Company’s automation platforms, or adverse effects from the use of or regulation of artificial intelligence and machine learning tools, any of which could result in a negative effect on the Company’s performance of services, a loss of business or increased costs, damages to the Company’s reputation, significant litigation exposure, an inability to meet required financial reporting deadlines, or the failure to meet future regulatory or customer information technology, data security and connectivity requirements;
35.business interruption, increased costs, and other adverse effects on the Company’s operations due to the unionization of employees, union strikes, work stoppages, general labor unrest or failure to comply with labor or employment laws;
36.failure to maintain the Company’s days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement arising from unfavorable changes in third-party payer policies, payment delays introduced by third-party utilization management organizations, and increasing levels of patient payment responsibility;
37.impact on the Company’s revenues, cash collections, and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets or in the Company's credit ratings by Standard & Poor’s and/or Moody’s;
38.failure to maintain the expected capital structure for the Company, including failure to maintain the Company's investment grade rating, or leverage ratio covenants under its revolving credit facility;
39.changes in reimbursement by foreign governments and foreign currency fluctuations;
40.inability to obtain certain billing information from physicians, resulting in increased costs and complexity, a temporary disruption in receipts, and ongoing reductions in reimbursements and revenues;
41.expenses and risks associated with international operations, including, but not limited to, compliance with the U.S. Foreign Corrupt Practices Act (FCPA), the U.K. Bribery Act, other applicable anti-corruption laws and regulations, trade sanction laws and regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions;
42.failure to achieve expected efficiencies, benefits, and savings in connection with the Company’s business process improvement initiatives;
43.changes in tax laws and regulations or changes in their interpretation;
44.changing global economic conditions and government and regulatory changes;
45.risks associated with the impacts and expected benefits and costs of the recently completed spin-off of Fortrea, including but not limited to factors that could adversely affect the Company’s ability to realize the expected benefits of the spin-off, the failure of the spin-off to qualify as a tax-free transaction for U.S. federal income tax purposes, and potential exposure to unexpected claims, liabilities, or costs under the Company’s agreements with Fortrea and/or otherwise in connection with the spin-off; and
46.risks and uncertainties as to the completion, timing, and expected benefits of the planned holding company reorganization (Reorganization), including, but not limited to the effect of the announcement of the Reorganization on the company's business generally, market reaction to the announcement, and unexpected issues that may arise in the continued planning for the Reorganization.
23

INDEX
Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Given these uncertainties, one should not put undue reliance on any forward-looking statements
Separation of Fortrea Holdings Inc.
On June 30, 2023, Labcorp completed the previously announced separation of Fortrea from the Company.
All historical operating results of Fortrea are presented as Discontinued Operations, net of tax, in the consolidated statement of operations. The spin-off is expected to be treated as tax-free for the Company and its shareholders for U.S. federal income tax purposes.
As a result of the separation of Fortrea, the Company recast segment results to exclude the historical results of the CDCS business for all periods presented. The remaining operations of the previously reported Drug Development segment have been renamed the Biopharma Laboratory Services segment.
GENERAL (dollars in millions, except per share data)
Revenues for the three months ended March 31, 2024, were $3,176.6, an increase of 4.6% from $3,037.8 during the three months ended March 31, 2023. The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures, of 1.8%, and favorable foreign currency translation of 0.5%. The 2.3% increase in organic revenue was driven by a 4.2% increase in the company's organic Base Business, partially offset by a 1.9% decrease in COVID-19 PCR testing (COVID-19 Testing). Base Business includes Labcorp's operations except for COVID-19 Testing.
The Company defines organic growth as the increase in revenue excluding the year-over-year impact of acquisitions, divestitures, and currency. Acquisition and divestiture impact is considered for a twelve month period following the close of each transaction.
RESULTS OF OPERATIONS (dollars in millions)
Three months ended March 31, 2024, compared with three months ended March 31, 2023
Revenues

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Dx | $ | 2,479.7 |  |  | $ | 2,382.8 |  |  | 4.1 | %
BLS | 710.9 |  |  | 661.3 |  |  | 7.5 | %
Intercompany eliminations and other | (14.0) |  |  | (6.3) |  |  | 122.2 | %
Total | $ | 3,176.6 |  |  | $ | 3,037.8 |  |  | 4.6 | %

Total revenues for the three months ended March 31, 2024, were $3,176.6, an increase of 4.6% over $3,037.8 in the first quarter of 2023. The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures, of 1.8%, and favorable foreign currency translation of 0.5%. The 2.3% increase in organic revenue was driven by a 4.2% increase in the company's organic Base Business, partially offset by a 1.9% decrease in COVID-19 Testing. Base Business includes Labcorp's operations except for COVID-19 Testing.
Dx revenues for the three months ended March 31, 2024, were $2,479.7, an increase of 4.1% over $2,382.8 in the first quarter of 2023. The increase was due to organic revenue of 1.8% and acquisitions, net of divestitures, of 2.2%. The 1.8% increase in organic growth was due to a 4.3% increase in the Base Business, partially offset by a 2.5% decrease in COVID-19 Testing. Total Base Business growth compared to the Base Business in the prior year was 6.8%.
Dx total volume (measured by requisitions) for the three months ended March 31, 2024, increased by 3.4% as acquisition volume, net of divestitures, contributed 2.2%, while organic volume increased by 1.2%. Organic volume was up due to a 2.6% increase in the Base Business, including the negative impact from adverse weather of 1%. This was partially offset by a 1.4% decrease in COVID-19 Testing. Price/mix increased by 0.6% due to organic Base Business growth of 1.7%, partially offset by a decrease in COVID-19 Testing of 1.1%. Base Business volume increased 4.9% compared to the Base Business last year. Price/mix was up 1.9% in the Base Business compared to the Base Business last year.
BLS revenues for the three months ended March 31, 2024, were $710.9, an increase of 7.5% over $661.3 in the first quarter of 2023. The increase was due to organic growth of 5.1% and favorable foreign currency translation of 2.4%.
24

INDEX
Cost of Revenues

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Cost of revenues | $ | 2,279.3 |  |  | $ | 2,187.7 |  |  | 4.2 | %
Cost of revenues as a % of revenues | 71.8 | % |  | 72.0 | % |  |

Cost of revenues increased 4.2% during the three months ended March 31, 2024, as compared with the corresponding period in 2023. Cost of revenues as a percentage of revenues during the three months ended March 31, 2024, decreased to 71.8% as compared to 72.0% in the corresponding period in 2023. This decrease in cost of revenues as a percent of revenues was primarily due to LaunchPad savings and CDCS costs during the first quarter of 2023 that do not qualify as discontinued operations, largely offset by higher personnel costs and lower COVID-19 Testing.
Selling, General and Administrative Expenses

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Selling, general and administrative expenses | $ | 508.4 |  |  | $ | 457.2 |  |  | 11.2 | %
Selling, general and administrative expenses as a % of revenues | 16.0 | % |  | 15.1 | % |  |

Selling, general and administrative expenses as a percentage of revenues was 16.0% and 15.1% during the three months ended March 31, 2024, and 2023, respectively. The increase is primarily due to higher personnel costs and a reduction in COVID-19 Testing revenues.
Amortization of Intangibles and Other Assets

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Amortization of intangibles and other assets | $ | 60.1 |  |  | $ | 53.4 |  |  | 12.6 | %

The increase in amortization of intangibles and other assets primarily reflects additional amortization for assets acquired subsequent to March 31, 2023.
Goodwill and Other Asset Impairments

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Goodwill and other asset impairments | $ | 2.5 |  |  | $ | 2.2 |  |  | 13.6 | %

The Company recorded impairment charges of $2.5 during the three months ended March 31, 2024 related to a decommissioned robotic asset. The Company recorded impairment charges of $2.2 in capitalized software costs during the three months ended March 31, 2023.
Restructuring and Other Charges

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Restructuring and other charges | $ | 5.0 |  |  | $ | 7.5 |  |  | (33.6) | %

During the three months ended March 31, 2024, the Company recorded net restructuring and other charges of $5.0. The charges were comprised of $5.8 related to severance and other personnel costs. The charges were adjusted by the reversal of a previously established liability of $0.8 in unused facility-related costs.
During the three months ended March 31, 2023, the Company recorded net restructuring and other charges of $7.5. The charges were comprised of $4.0 related to severance and other personnel costs and $4.3 in facility closures, lease terminations, and general integration activities. The charges were adjusted by the reversal of a previously established liability of $0.5 in unused severance liabilities and the increase of a previously established liability of $0.3 in facility-related costs.
Interest Expense

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Interest expense | $ | (46.9) |  |  | $ | (50.7) |  |  | (7.5) | %

The decrease in interest expense for the three months ended March 31, 2024, as compared with the corresponding period in 2023, is primarily due to decreased borrowings under the Company's revolving credit facility, repayment of the November 2023 $300.0 senior notes, and partially offset by a higher interest rate on variable rate debt.
25

INDEX
Equity Method Income

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Equity method income, net | $ | 0.1 |  |  | $ | (2.1) |  |  | (102.7) | %

Equity method income represents the Company's ownership share in joint venture partnerships along with equity investments in other companies in the health care industry. The increase in income for the three months ended March 31, 2024, as compared with the corresponding period in 2023, was partially due to the sale of the Company's interest in one joint venture and the acquisition of the remaining interest in another joint venture during 2023.
Other, net

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Other, net | $ | 20.0 |  |  | $ | (6.9) |  |  | (390.0) | %

The change in Other, net for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, is primarily due to $22.4 of transition services fees charged to Fortrea related to administrative and IT systems support. The costs to provide these services are included in operating income but the service fees are included in other income. In addition, the Company recorded investment losses of $4.2 for the three months ended March 31, 2024 compared to investment losses of $1.5 for the corresponding period of 2023. Foreign currency transaction losses of $3.3 were recognized for the three months ended March 31, 2024, as compared to gains of $3.6 for the corresponding period of 2023. The Company also recorded a $4.9 gain on the sale of the assets of its Beacon Laboratory Benefit Solutions, Inc. business in 2024.
Income Tax Expense

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Income tax expense | $ | 69.1 |  |  | $ | 63.9 |  |  | 8.2 | %
Income tax expense as a % of earnings before income taxes | 23.2 | % |  | 23.5 | % |  |

The current year and prior year effective tax rate differs from the U.S. federal statutory rate of 21.0% primarily due to state income taxes and the disallowance of certain executive compensation, which were partially offset by research and development tax credits and favorable foreign rate differentials.
Operating Income by Segment
As a result of the spin-off of Fortrea, the Company recast the segment results to exclude the historical results of the CDCS business for all periods presented. The remaining operations of the previously reported Drug Development segment have been renamed the Biopharma Laboratory Services segment.

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  | Change
Dx segment operating income | $ | 417.9 |  |  | $ | 441.5 |  |  | (5.3) | %
Dx segment operating margin | 16.9 | % |  | 18.5 | % |  | (1.7) | %
BLS segment operating income | 99.9 |  |  | 73.6 |  |  | 35.7 | %
BLS segment operating margin | 14.1 | % |  | 11.1 | % |  | 2.9 | %
Segment operating income | 517.8 |  |  | 515.1 |  |  | 0.5 | %
General corporate and unallocated expenses | (128.9) |  |  | (122.2) |  |  | 5.5 | %
Amortization of intangibles and other assets | (60.1) |  |  | (53.4) |  |  | 12.6 | %
Restructuring and other charges | (5.0) |  |  | (7.5) |  |  | (33.6) | %
Goodwill and other asset impairments | (2.5) |  |  | (2.2) |  |  | 13.6 | %
Total operating income | $ | 321.3 |  |  | $ | 329.8 |  |  | (2.6) | %

Dx operating income was $417.9 for the three months ended March 31, 2024, a decrease of $23.6 over operating income of $441.5 in the corresponding period of 2023, and Dx operating margin decreased 170 basis points year-over-year. The decrease in adjusted operating income margin was due to a reduction in COVID-19 Testing, adverse weather and the mix impact from lab management agreements, which is expected to improve over time.
BLS operating income was $99.9 for the three months ended March 31, 2024, an increase of $26.3 over operating income of $73.6 in the corresponding period of 2023. The increase was due to organic growth and LaunchPad savings, partially offset by higher personnel expense.
26

INDEX
General corporate and unallocated expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. General corporate and unallocated expenses were $128.9 for the three months ended March 31, 2024, an increase of $6.7 over corporate expenses of $122.2 in the corresponding period of 2023, primarily due to costs related to the spin-off of Fortrea, personnel costs, and research and development costs.
The Company remains on track to deliver approximately $350.0 of net savings from its three-year LaunchPad initiative by the end of 2024 and approximately $100.0 to $125.0 of savings in fiscal 2024.
LIQUIDITY AND CAPITAL RESOURCES (dollars and shares in millions)
The Company's cash-generating ability and financial condition typically have provided ready access to capital markets. The Company's principal source of liquidity is operating cash flow, supplemented by proceeds from debt offerings. The Company believes that its balances of cash and cash equivalents and borrowing capacity, along with cash generated from operations, will be sufficient to satisfy its cash requirements, cash dividends, and share repurchases over the next twelve months and beyond. The Company's senior unsecured revolving credit facility is further discussed in Note 7 (Debt) to the Company's condensed consolidated financial statements.
In summary, the Company's cash flows from continuing operations were as follows for the three months ended March 31, 2024, and 2023, respectively:

| Three Months Ended March 31,
| 2024 |  | 2023
Net cash provided by (used for) operating activities from continuing operations | $ | (29.8) |  |  | $ | 185.7 |
Net cash used for investing activities from continuing operations | (393.1) |  |  | (84.0) |
Net cash used for financing activities from continuing operations | (11.7) |  |  | (60.6) |
Effect of exchange rate changes on cash and cash equivalents | (2.9) |  |  | 3.0 |
Net increase (decrease) in cash and cash equivalents from continuing operations | $ | (437.5) |  |  | $ | 44.1 |

Cash and Cash Equivalents
Cash and cash equivalents at March 31, 2024, and 2023, totaled $99.3 and $294.8, respectively. Cash and cash equivalents consist of highly liquid instruments, such as time deposits, commercial paper, and other money market investments, which have original maturities of three months or less.
Cash Flows from Operating Activities
During the three months ended March 31, 2024, the Company's continuing operations used $29.8 of cash as compared to providing $185.7 during the same period in 2023. The $215.5 decrease in cash provided from operations in 2024 as compared with the corresponding 2023 period is primarily due to lower cash earnings and the timing of working capital requirements.
Cash Flows from Investing Activities
Net cash used for investing activities from continuing operations for the three months ended March 31, 2024, was $393.1 as compared to $84.0 for the three months ended March 31, 2023. The change in cash used for investing activities was primarily due to an increase in business acquisitions and higher capital expenditures during the three months ended March 31, 2024. Capital expenditures were $133.8 and $78.2 for the three months ended March 31, 2024, and 2023, respectively.
Cash Flows from Financing Activities
Net cash used by financing activities from continuing operations for the three months ended March 31, 2024, was $11.7 as compared to $60.6 for the three months ended March 31, 2023. The change in cash flows from financing activities from continuing operations for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, was primarily due to net proceeds from revolving credit facilities of $42.4 in 2024.
At March 31, 2024, the Company had $99.3 of cash and $957.6 of available borrowings under its revolving credit facility, which does not mature until 2026. Under the Company's revolving credit facility and indentures relating to the Company's senior notes, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers , and with respect to the revolving credit facility, the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants under the revolving credit facility and the indentures related to the Company's outstanding senior notes at March 31, 2024. The Company expects that it will remain in compliance with all covenants associated with its existing debt obligations for the next twelve months.
The Company continues to evaluate its outstanding debt portfolio to take advantage of market conditions that would allow the Company to maintain a reasonable interest rate and lower financing risk. The Company anticipates that it will refinance the $2,000.0 in debt coming due during the next 12 months.
27

INDEX
As of March 31, 2024, the Company had outstanding authorization from the board of directors to purchase up to $531.5 of the Company's common stock.
For the three months ended March 31, 2024, the Company paid $62.1 in common stock dividends. On April 11, 2024, the Company announced a cash dividend of $0.72 per share of common stock for the second quarter, or approximately $61.4 in the aggregate. The dividend will be payable on June 12, 2024, to stockholders of record of all issued and outstanding shares of common stock as of the close of business on May 28, 2024. The declaration and payment of any future dividends will be at the discretion of the Company’s board of directors.
Credit Ratings
The Company’s investment grade debt ratings from Moody’s and from Standard and Poor’s (S&P) contribute to its ability to access capital markets.
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk (dollars in millions)
Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates, interest rates, and other relevant market rate or price changes. In the ordinary course of business, the Company is exposed to various market risks, including changes in foreign currency exchange and interest rates, and the Company regularly evaluates its exposure to such changes. The Company addresses its exposure to market risks, principally the market risks associated with changes in foreign currency exchange rates and interest rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as foreign currency forward contracts, and interest rate and cross currency swap agreements.
Foreign Currency Exchange Rates
Approximately 13.8% of the Company’s revenues for the three months ended March 31, 2024, and approximately 13.4% of the Company’s revenue for the three months ended March 31, 2023, were denominated in currencies other than the U.S. Dollar (USD). The Company’s financial statements are reported in USD and, accordingly, fluctuations in exchange rates will affect the translation of revenues and expenses denominated in foreign currencies into USD for purposes of reporting the Company’s consolidated financial results. In the first quarter of 2024 and the year ended December 31, 2023, the most significant currency exchange rate exposures were to the Canadian dollar, Swiss Franc, Euro and British Pound. Excluding the impacts from any outstanding or future hedging transactions, a hypothetical change of 10% in average exchange rates used to translate all foreign currencies to USD would have impacted income before income taxes for the three months ended March 31, 2024, by approximately $6.5. Gross accumulated currency translation adjustments recorded as a separate component of shareholders’ equity were $(124.3) and $48.1 at March 31, 2024 and 2023, respectively. The Company does not have significant operations in countries in which the economy is considered to be highly inflationary.
The Company earns revenue from service contracts over a period of time, ranging from months to years. Accordingly, exchange rate fluctuations during this period may affect the Company’s profitability with respect to such contracts. The Company is also subject to foreign currency transaction risk for fluctuations in exchange rates during the period of time between the consummation and cash settlement of transactions. The Company limits its foreign currency transaction risk through exchange rate fluctuation provisions stated in some of its contracts with customers, or it may hedge transaction risk with foreign currency forward contracts. At March 31, 2024, the Company had 9 open foreign exchange forward contracts with various amounts maturing monthly through April 2024 with a notional value totaling approximately $279.9. At December 31, 2023, the Company had 9 open foreign exchange forward contracts with various amounts maturing monthly through January 2024 with a notional value totaling approximately $305.8.
The Company is party to USD to Swiss Franc cross-currency swap agreements with an aggregate notional amount of $600.0, $300.0 maturing in 2031 and $300.0 maturing in 2034, as a hedge against the impact of foreign exchange movements on its net investment in a Swiss Franc functional currency subsidiary.
Interest Rates
Some of the Company’s debt from time to time is subject to interest at variable rates. As a result, fluctuations in interest rates can affect the business. The Company attempts to manage interest rate risk and overall borrowing costs through an appropriate mix of fixed and variable rate debt including by the utilization of derivative financial instruments, primarily interest rate swaps.
Borrowings under the Company’s term loan credit facility, now repaid, and revolving credit facility are subject to variable interest rates, unless fixed through interest rate swaps or other agreements.
28

INDEX
In May 2021, to hedge against changes in the fair value portion of the Company’s long-term debt, the Company entered into fixed-to-variable interest rate swap agreements for the 2.70% senior notes due 2031 with an aggregate notional value of $500.0 and variable interest rates based on three-month SOFR plus 1.0706%.
ITEM 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out, under the supervision and with the participation of the Company’s management, including the Company’s principal executive officer and principal financial officer, an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules13a-15 and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon this evaluation, the Company’s principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2024.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal control over financial reporting (as defined in Rules13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) that occurred during the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
29

INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
PART I - OTHER INFORMATION
Item 1. Legal Proceedings
See Note 9 (Commitments and Contingencies) to the Company’s condensed consolidated financial statements, above, which is incorporated herein by reference.
Item 1A. Risk Factors
The risk factors set forth below revise and supplement the corresponding risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. With the exception of the following, there have been no material changes in the risk factors that appear in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
U.S. Food and Drug Administration (FDA) regulation of diagnostic products, increased FDA regulation of laboratory-developed tests (LDTs), and regulation by other countries of diagnostic tests and related products could result in increased costs and the imposition of fines or penalties, and could have a material adverse effect upon the Company’s business.
The FDA has regulatory responsibility for instruments, test kits, reagents and other devices used by clinical laboratories. The FDA enforces laws and regulations that govern the development, testing, manufacturing, performance, labeling, advertising, marketing, distribution, and surveillance of diagnostic products, and it regularly inspects and reviews the manufacturing processes and product performance of diagnostic products. Dx’s point-of-care testing devices are subject to regulation by the FDA.
LDTs developed by high complexity clinical laboratories are currently generally offered as services to health care providers under the CLIA regulatory framework administered by CMS, without the requirement for FDA clearance or approval. However, since the 1990s, the FDA has asserted that it has authority to regulate LDTs as medical devices but has exercised enforcement discretion to refrain from systematic regulation of LDTs. In 2014, the FDA issued draft guidance describing how it intended to discontinue its enforcement discretion policy and begin regulating LDTs as medical devices; however, that draft guidance was not finalized, and the FDA instead continued its enforcement discretion policy and indicated that it intended to work with Congress to enact comprehensive legislative reform of diagnostics oversight. In February 2020, the FDA issued a statement with a table of pharmacogenetic associations setting forth certain gene-drug interactions that the agency determined are supported by the scientific literature to help ensure that claims being made for pharmacogenetic tests are grounded in sound science, thereby reducing the risk of enforcement actions with respect to LDTs offering claims consistent with the table. The FDA noted that it could take enforcement actions under the current medical device framework regarding diagnostic claims the agency determines not to be sufficiently supported. In addition, in 2021, the Verifying Accurate, Leading-edge, IVCT Development (VALID) Act was introduced in Congress and provided a framework to regulate in vitro diagnostics and LDTs as in vitro clinical tests. In 2022, the VALID Act was incorporated into the Senate user fee bill but was not included in the year-end Consolidated Appropriations Act of 2022. On March 29, 2023, the VALID Act was reintroduced and remains pending. On April 29, 2024, the FDA released a final rule purporting to clarify its authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act, under which it will phase out its general enforcement discretion approach for LDTs under a four-year period subject to certain continuing enforcement discretion policies. More specifically, among other policies, the final rule provides that the FDA will continue to exercise discretion not to enforce premarket review and most FDA quality system requirements for unmodified LDTs first marketed prior to issuance of the final rule; will continue to exercise discretion not to enforce premarket review requirements for LDTs approved by the State of New York; and will continue to exercise discretion not to enforce premarket review and most FDA quality system requirements for LDTs developed and performed by a laboratory integrated into a health system for unmet needs for patients under the care of the same health system, where no FDA cleared or approved test is available. The Company continues to evaluate the final rule, and it is likely there will be legal challenges that may change the final rule or delay or prevent its enforcement; however, issuance of the final rule presents an increased risk of FDA enforcement actions for laboratory tests offered by companies without FDA clearance or approval that do not fall within the ongoing enforcement discretion policies. However, the outcome and its ultimate impact on the Company’s business remain difficult to predict at this time.
Current FDA regulation of the Company’s diagnostic products and the potential for future increased regulation of the Company’s LDTs could result in increased costs and administrative and legal actions for noncompliance, including warning letters, fines, penalties, product suspensions, product recalls, injunctions, and other civil and criminal sanctions, and could impair the development and commercialization of new tests, which could have a material adverse effect upon the Company.
Regulation of diagnostics products in jurisdictions outside the U.S. in which the Company operates may impact laboratory testing offered by the Company in both Dx and BLS. For example, the European Union In Vitro Diagnostics Regulation (Regulation (EU) 2017/746 (EU IVDR)) established a new legislative framework for in vitro diagnostic devices that are used in
30

INDEX
certain circumstances, and includes a rule-based classification and quality and safety standards. The EU IVDR, where applicable to BLS's services, could impact BLS's ability to support trials, result in increased costs and administrative and legal actions, and have an adverse effect.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds (dollars and shares in millions, except per share data)
During the three months ended March 31, 2024, the Company did not repurchase any of its common stock.

| Total Number of Shares Repurchased |  | Average Price Paid Per Share |  | Total Number of Shares Repurchased as Part of Publicly Announced Program |  | Maximum Dollar Value of Shares that May Yet Be Repurchased Under the Program
January 1 - January 31 | — |  |  | — |  |  | — |  |  | 531.5 |
February 1 -February 29 | — |  |  | — |  |  | — |  |  | 531.5 |
March 1 - March 31 | — |  |  | — |  |  | — |  |  | 531.5 |
| — |  |  | $ | — |  |  | — |  |  | $ | 531.5 |

As of March 31, 2024, the Company had outstanding authorization from the board of directors to purchase up to $531.5 of the Company's common stock. The repurchase authorization has no expiration date.
Item 5. Other Information
During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The Reorganization
On April 25, 2024, the Company announced that it intends to implement a new holding company structure on May 17, 2024. The name of the new holding company will be Labcorp Holdings Inc. Labcorp Holdings Inc. will replace Laboratory Corporation of America Holdings as the publicly-traded entity and Laboratory Corporation of America Holdings will become a wholly owned subsidiary of Labcorp Holdings Inc. The name “Labcorp Holdings Inc.” is more closely aligned with our brand name, and the company will have a structure that is optimized to reflect our operations. Common stock will continue to trade on the NYSE on an uninterrupted basis under the existing symbol “LH” and Laboratory Corporation of America Holdings stockholders will automatically become stockholders of Labcorp Holdings Inc. on a one-for-one basis with all of the same rights.
Item 6. Exhibits

(a) |
10.1*+ | Amended and Restated Laboratory Corporation of America Holdings Master Senior Executive Severance Plan
31.1* | Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
31.2* | Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
32** | Written Statement of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)
101.INS* | Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH* | Inline XBRL Taxonomy Extension Schema
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)

* |  | filed herewith
** |  | furnished herewith
+ |  | Management contracts or compensatory plans or arrangements

31

INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant

| By: | /s/ ADAM H. SCHECHTER
|  | Adam H. Schechter
|  | Chief Executive Officer

| By: | /s/ GLENN A. EISENBERG
|  | Glenn A. Eisenberg
|  | Executive Vice President and
|  | Chief Financial Officer

April 30, 2024
32